(antiepileptic AND drug) OR (drug AND strongly) OR (spina AND bifida)
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"To successfully target Notch receptors as part of a multidrug anticancer strategy, it will be essential to fully characterize the factors that are modulated by Notch signaling. We recently reported that Notch3 silencing in HCC results in p53 up-regulation in vitro and, therefore, we focused on the mechanisms that associate Notch3 to p53 protein expression. We explored the regulation of p53 by Notch3 signalling in three HCC cell lines HepG2, SNU398 and Hep3B.We found that Notch3 regulates p53 at post-transcriptional level controlling both Cyclin G1 expression and the feed-forward circuit involving p53, miR-221 and MDM2. Moreover, our results were validated in human HCCs and in a rat model of HCC treated with Notch3 siRNAs. Our findings are becoming an exciting area for further in-depth research toward targeted inactivation of Notch3 receptor as a novel therapeutic approach for increasing the drug-sensitivity, and thereby improving the treatment outcome of patients affected by HCC. Indeed, we proved that Notch3 silencing strongly increases the effects of Nutilin-3.With regard to therapeutic implications, Notch3-specific drugs could represent a valuable strategy to limit Notch signaling in the context of hepatocellular carcinoma over-expressing this receptor.","fulltextAvailable":false,"journal":"Oncotarget","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hep G2 Cells","uri":{"id":"D056945","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Hepatocellular","uri":{"id":"D006528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Notch","uri":{"id":"D051880","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclin G1","uri":{"id":"D056766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Axis","uri":{"id":"D001368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclins","uri":{"id":"D016213","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25431954","title":"Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Camptothecin-polylactide conjugates (CMPT-PLA) were synthesized by covalent incorporation of CMPT into PLA of different microstructure, i.e., atactic PLA and atactic-block-isotactically enriched PLA (Pm = 0.79) via urethane bonds. The kinetic release of CPMT from CMPT-PLA conjugates, tested in vitro under different conditions, is possible in both cases and notably, strongly dependent on PLA microstructure. It shows that release properties of drug-PLA conjugates can be tailored by controlled design of the PLA microstructure, and allow in the case of CMPT-PLA conjugates for the development of highly controlled biodegradable CMPT systems-important delivery systems for anti-cancer agents.","fulltextAvailable":false,"journal":"Molecules (Basel, Switzerland)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Camptothecin","uri":{"id":"D002166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kinetics","uri":{"id":"D007700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urethane","uri":{"id":"D014520","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25429566","title":"Polylactide conjugates of camptothecin with different drug release abilities.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Mantle cell lymphoma (MCL) is an aggressive, incurable disease, characterized by a deregulated cell cycle. Chk1 and Wee1 are main regulators of cell cycle progression and recent data on solid tumors suggest that simultaneous inhibition of these proteins has a strong synergistic cytotoxic effect. The effects of a Chk1 inhibitor (PF-00477736) and a Wee1 inhibitor (MK-1775) have been herein investigated in a large panel of mature B-cell lymphoma cell lines. We found that MCL cells were the most sensitive to the Chk1 inhibitor PF-00477736 and Wee1 inhibitor MK-1775 as single agents. Possible involvement of the translocation t(11;14) in Chk1 inhibitor sensitivity was hypothesized. The combined inhibition of Chk1 and Wee1 was strongly synergistic in MCL cells, leading to deregulation of the cell cycle, with increased activity of CDK2 and CDK1, and activation of apoptosis. In vivo treatment with the drug combination of mice bearing JeKo-1 xenografts (MCL) had a marked antitumor effect with tumor regressions observed at non-toxic doses (best T/C%=0.54%). Gene expression profiling suggested effect on genes involved in apoptosis. The strong synergism observed by combining Chk1 and Wee1 inhibitors in preclinical models of MCL provides the rationale for testing this combination in the clinical setting.","fulltextAvailable":false,"journal":"Oncotarget","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma, B-Cell","uri":{"id":"D016393","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma, Mantle-Cell","uri":{"id":"D020522","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocytes","uri":{"id":"D001402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma","uri":{"id":"D008223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25428911","title":"Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Fluorescence spectroscopy in combination with circular dichroism (CD) and ultraviolet-visible (UV-vis) absorption spectroscopy were employed to investigate the binding of a new platinum(II) complex containing an antiepileptic drug \"Levetiracetam\" to bovine serum albumin (BSA) under the physiological conditions. In the mechanism discussion, it was proved that the fluorescence quenching of BSA by Pt(II) complex is a result of the formation of Pt(II) complex-BSA complex. The thermodynamic parameters ΔG, ΔH, and ΔS at different temperatures (283, 298, and 310 K) were calculated, and the negative value for ΔH and ΔS indicate that the hydrogen bonds and van der Waals interactions play major roles in Pt(II) complex-BSA association. Binding studies concerning the number of binding sites (n~1) and apparent binding constant K b were performed by fluorescence quenching method. The site marker competitive experiments indicated that the binding of Pt(II) complex to BSA primarily took place in site II. Based on the Förster's theory, the average binding distance between Pt(II) complex and BSA was obtained (r = 5.29 nm). Furthermore, UV-vis, CD, and synchronous fluorescence spectrum were used to investigate the structural change of BSA molecules with addition of Pt(II) complex. These results indicate that the binding of Pt(II) complex to BSA causes apparent change in the secondary structure of BSA and do affect the microenvironment around the tryptophan residue.","fulltextAvailable":false,"journal":"Applied biochemistry and biotechnology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Binding Sites","uri":{"id":"D001665","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen Bonding","uri":{"id":"D006860","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrometry, Fluorescence","uri":{"id":"D013050","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Circular Dichroism","uri":{"id":"D002942","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Albumin","uri":{"id":"D012709","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Albumin, Bovine","uri":{"id":"D012710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Albumins","uri":{"id":"D000418","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen","uri":{"id":"D006859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogenation","uri":{"id":"D006865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platinum","uri":{"id":"D010984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Temperature","uri":{"id":"D013696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thermodynamics","uri":{"id":"D013816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tryptophan","uri":{"id":"D014364","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25427597","title":"Mechanistic and Conformational Studies on the Interaction of a Platinum(II) Complex Containing an Antiepileptic Drug, Levetiracetam, With Bovine Serum Albumin by Optical Spectroscopic Techniques in Aqueous Solution.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"ABL tyrosine kinase inhibitors (TKI) like Imatinib, Dasatinib and Nilotinib are the gold standard in conventional treatment of CML. However, the emergence of resistance remains a major problem. Alternative therapeutic strategies of ABL TKI-resistant CML are urgently needed. We asked whether dual inhibition of BCR-ABL and Aurora kinases A-C could overcome resistance mediated by ABL kinase mutations. We therefore tested the dual ABL and Aurora kinase inhibitors PHA-739358 and R763/AS703569 in Ba/F3- cells ectopically expressing wild type (wt) or TKI-resistant BCR-ABL mutants. We show that both compounds exhibited strong anti-proliferative and pro-apoptotic activity in ABL TKI resistant cell lines including cells expressing the strongly resistant T315I mutation. Cell cycle analysis indicated polyploidisation, a consequence of continued cell cycle progression in the absence of cell division by Aurora kinase inhibition. Experiments using drug resistant variants of Aurora B indicated that PHA-739358 acts on both, BCR-ABL and Aurora Kinase B, whereas Aurora kinase B inhibition might be sufficient for the anti-proliferative activity observed with R763/AS703569. Taken together, our data demonstrate that dual ABL and Aurora kinase inhibition might be used to overcome ABL TKI resistant CML.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Division","uri":{"id":"D002455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein-Tyrosine Kinases","uri":{"id":"D011505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aurora Kinase B","uri":{"id":"D064107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aurora Kinases","uri":{"id":"D064127","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyploidy","uri":{"id":"D011123","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tyrosine","uri":{"id":"D014443","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25426931","title":"Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: IntroductionThe establishment of drug resistance following treatment with chemotherapeutics is strongly associated with poor clinical outcome in patients, and drugs that target chemoresistant tumors have the potential to increase patient survival. In an effort to identify biological pathways of chemoresistant breast cancers that can be targeted therapeutically, a small molecule screen utilizing metastatic patient-derived breast cancer cells was conducted; from this previous report, the cytotoxic small molecule, C-6, was identified for its ability to selectively kill aggressive breast cancer cells in a caspase independent manner. Here, we describe the cellular and molecular pathways induced following C-6 treatment in both normal and breast cancer cell lines.MethodsTranscriptome analyses and protein expression experiments were used to measure endoplasmic reticulum (ER) stress following C-6 treatment. Studies utilizing transmission electron microscopy and metabolomic profiling were conducted to characterize mitochondrial morphology and function in C-6 treated cells. Oxygen consumption rates and oxidative stress were also measured in breast cancer and normal mammary epithelial cells following treatment with the small molecule. Finally, structural modifications were made to the molecule and potency and cancer-selectivity were evaluated.ResultsTreatment with C-6 resulted in ER stress in both breast cancer cells and normal mammary epithelial cells. Gross morphological defects were observed in the mitochondria and these aberrations were associated with metabolic imbalances and a diminished capacity for respiration. Following treatment with C-6, oxidative stress was observed in three breast cancer cell lines but not in normal mammary epithelial cells. Finally, synthetic modifications made to the small molecule resulted in the identification of the structural components that contribute to C-6¿s cancer-selective phenotype.ConclusionsThe data reported here implicate mitochondrial and ER stress as a component of C6¿s biological activity and provide insight into non-apoptotic cell death mechanisms; targeting biological pathways that induce mitochondrial dysfunction and ER stress may offer new strategies for the development of therapeutics that are effective against chemoresistant breast cancers.","fulltextAvailable":false,"journal":"Breast cancer research : BCR","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum Stress","uri":{"id":"D059865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum","uri":{"id":"D004721","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epithelial Cells","uri":{"id":"D004847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen Consumption","uri":{"id":"D010101","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Design","uri":{"id":"D012107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Transmission","uri":{"id":"D046529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Death","uri":{"id":"D016923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum Stress","uri":{"id":"D059865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homicide","uri":{"id":"D006708","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen","uri":{"id":"D010100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygenators","uri":{"id":"D010106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ventilators, Mechanical","uri":{"id":"D012122","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caspases","uri":{"id":"D020169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolomics","uri":{"id":"D055432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolome","uri":{"id":"D055442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitochondria","uri":{"id":"D008928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiration","uri":{"id":"D012119","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25425314","title":"The small molecule C-6 is selectively cytotoxic against breast cancer cells and its biological action is characterized by mitochondrial defects and endoplasmic reticulum stress.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Electroconvulsive therapy (ECT) is an effective and safe treatment method for a variety of psychiatric disorders, including major depressive disorder. Although there is no absolute contraindication to ECT, clinicians often hesitate to apply this method to patients with a skull defect. We report a case of ECT performed on a major depressive disorder patient with an open wound after craniectomy. We summarize successful ECT cases of patients with a permanent skull defect and discuss various factors that may influence ECT outcomes in patients with a skull defect, including electrode placement, benzodiazepines, and anticonvulsants.","fulltextAvailable":false,"journal":"Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depressive Disorder, Major","uri":{"id":"D003865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depressive Disorder","uri":{"id":"D003866","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroconvulsive Therapy","uri":{"id":"D004565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrodes","uri":{"id":"D004566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skull","uri":{"id":"D012886","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Advance Directives","uri":{"id":"D016223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzodiazepines","uri":{"id":"D001569","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25425066","title":"Electroconvulsive therapy for major depressive disorder in a patient with a permanent skull defect: A case report.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: To compare the pharmacokinetics of intravenous (IV), oral immediate-release (IR) and oral modified-release (MR) formulations of mavoglurant in healthy subjects, and to assess the food effect on the MR formulation's input characteristics. METHODS: Plasma concentration-time data from two clinical studies in healthy volunteers were pooled and analysed using NONMEM®. Drug entry into the systemic circulation was modelled using a sum of inverse Gaussian (IG) functions as an input rate function, which was estimated specifically for each formulation and food state. RESULTS: Mavoglurant pharmacokinetics was best described by a two-compartment model with a sum of either two or three IG functions as input function. The mean absolute bioavailability from the MR formulation (0.387) was less than from the IR formulation (0.436). The MR formulation pharmacokinetics were significantly impacted by food: bioavailability was higher (0.508) and the input process was shorter (complete in approximately 36 versus 12 h for the fasted and fed states, respectively). CONCLUSIONS: Modelling and simulation of mavoglurant pharmacokinetics indicate that the MR formulation might provide a slightly lower steady-state concentration range with lower peaks (possibly better drug tolerance) than the IR formulation, and that the MR formulation's input properties strongly depend on the food conditions at drug administration.","fulltextAvailable":false,"journal":"Pharmaceutical research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food, Formulated","uri":{"id":"D005526","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Healthy Volunteers","uri":{"id":"D064368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Tolerance","uri":{"id":"D004361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eating","uri":{"id":"D004435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Volunteers","uri":{"id":"D014838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Availability","uri":{"id":"D001682","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25425054","title":"Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: In situ forming poly(lactic-co-glycolic acid) (PLGA) implants have not been strongly considered for bone applications because of their poor mechanical properties. Here, in situ forming scaffolds containing hydroxyapatite micro- and nanoparticles were characterized to determine their mechanical properties, injectability, and microarchitecture. Scaffolds were prepared with various concentrations of hydroxyapatite, as well as poly(β-amino ester) microparticles that facilitate drug delivery. Strength was increased three-fold, from 2 to 6 MPa, while compressive modulus was improved 6-fold, from 24 to 141 MPa, via the addition of 30% nano-hydroxyapatite, which provided greater benefits at equivalent concentrations compared to micro-hydroxyapatite. Scaffolds retained a uniformly porous microarchitecture, and hydroxyapatite particles were distributed evenly throughout the PLGA phase. Injectability, determined by the force required to inject 0.5 mL of material within 60 seconds, remained clinically acceptable at <50 N at 30% w/w hydroxyapatite and up to 10% w/w PBAE microparticles. Ex vivo injections into intact porcine femoral heads increased compressive modulus of trabecular bone from 81 to 180 MPa and strength from 3.5 to 5.9 MPa. This injectable scaffold offers mechanical reinforcement coupled with previously demonstrated drug delivery potential in a single injection for bone-weakening conditions, such as osteonecrosis or osteoporosis. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"Journal of biomedical materials research. Part A","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Synergism","uri":{"id":"D004357","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esters","uri":{"id":"D004952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxyapatites","uri":{"id":"D006882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteonecrosis","uri":{"id":"D010020","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Durapatite","uri":{"id":"D017886","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoporosis","uri":{"id":"D010024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reinforcement (Psychology)","uri":{"id":"D012054","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25424622","title":"Hydroxyapatite-Reinforced in Situ Forming PLGA Systems for Intraosseous Injection(3.)","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":null,"fulltextAvailable":false,"journal":"The Pan African medical journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25422695","title":"[Association of atypical neuroleptics with anticonvulsants and malignant syndrome (about two cases)].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Adverse cutaneous drug reactions (ACDRs) are the most commonly reported adverse drug events. The causative drugs and clinical patterns of ACDRs are different in various populations. This study was conducted to identify the clinical patterns, causative drugs and reasons for drug administration in patients hospitalized due to ACDR. MATERIALS AND METHODS: This retrospective study was carried out in a referral university hospital, Isfahan, Iran. The medical records of all patients who were hospitalized in the Dermatology Department due to ACDRs were reviewed covering an 8-year period between December 2006 and August 2013. RESULTS: A total number of 282 patients with the mean age of 29.48 ± 21.18 years were hospitalized in this time period, of which 61% were females. The most common clinical patterns regarding the final diagnosis were Stevens-Johnson syndrome (SJS) (32%), exanthematous drug eruptions (24.5%) and toxic epidermal necrolysis (TEN) (11%). Anticonvulsants were the most frequently implicated drug group (51.8%) followed by antibiotics (33.7%) and analgesics and non-steroidal anti-inflammatory drugs (5.7%). The most common cause of drug administration was seizure (30%) and then upper respiratory tract infections (12%). The frequency distribution of clinical types of reactions was different between age groups (P < 0.001). The severe types (SJS, TEN, drug rash with eosinophilia and systemic symptoms and overlap syndrome) were more frequent in the patients aged ≤50 years old (55.2%) compare to those aged ≤50 years (28%) (P = 0.001). CONCLUSION: The main causative drugs of ACDRs were anticonvulsants and antibiotics. However, the sever types of reactions were more prevalent.","fulltextAvailable":false,"journal":"Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Distribution Systems","uri":{"id":"D006750","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiratory Tract Infections","uri":{"id":"D012141","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, University","uri":{"id":"D006785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age Groups","uri":{"id":"D009273","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Eruptions","uri":{"id":"D003875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiratory System","uri":{"id":"D012137","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiratory Tract Infections","uri":{"id":"D012141","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stevens-Johnson Syndrome","uri":{"id":"D013262","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eosinophilia","uri":{"id":"D004802","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Iran","uri":{"id":"D007492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatology","uri":{"id":"D003880","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25422656","title":"Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Severe skin reactions occur less frequently with eslicarbazepine (ESL) than with the other aromatic anticonvulsants. We report the first case of cutaneous adverse drug reaction (CADR) to ESL and co-sensitization between ESL and betalactams. A 41-year-old white woman developed focal epilepsy due to a meningioma that was removed. As post-operatory complication, she suffered meningitis as well as a maculo-papular erythema caused by the treatment with meropenem. Subsequently, ESL was started and gradually increased until 800 mg/day. Twenty-five days later, the patient developed an Erythema Multiforme Major (EMM). Strong positive immediate reaction was induced by prick test with carbamazepine (CBZ) and ESL at 0.01 and 0.1% within 15 and 30 minutes; however the delayed reading at 48 hours was negative. The patient was not carrier of the HLA alleles A3101 and B1502 associated with CBZ induced EMM. The hypersensitivity pathogenic mechanism of EMM is unclear and a delayed hypersensitivity process is speculated. However, the patch and intradermal tests in our patient did not show a delayed reaction but an immediate cutaneous one. A first allergic episode may elicit a massive nonspecific activation of the immune system, providing an enhanced expression of co-stimulatory molecules that decreases the level of tolerance to other drugs. When prescribing ESL, we suggest ruling out previous CADR, especially to CBZ and oxcarbazepine but also other chemically unrelated drugs such as beta-lactams.","fulltextAvailable":false,"journal":"Journal of pharmacology & pharmacotherapeutics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System","uri":{"id":"D007107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemicals and Drugs","uri":{"id":"chemicals_and_drugs_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsies, Partial","uri":{"id":"D004828","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythema Multiforme","uri":{"id":"D004892","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity, Delayed","uri":{"id":"D006968","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intradermal Tests","uri":{"id":"D007428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythema","uri":{"id":"D004890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meninges","uri":{"id":"D008578","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningioma","uri":{"id":"D008579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningism","uri":{"id":"D008580","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningitis","uri":{"id":"D008581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reading","uri":{"id":"D011932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbamazepine","uri":{"id":"D002220","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"beta-Lactams","uri":{"id":"D047090","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25422574","title":"Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Drug overdose is a growing problem among adolescents. Clinical severity depends on the drug and ingested amount, which in some cases may be life-threatening. We present a clinical case of a previously healthy teenage girl who ingested 16.4 g of carbamazepine and 14.5 g of valproic acid. She presented with profound disturbance of consciousness and toxic levels of both drugs, raised in the first hours after the ingestion. She was successfully treated with charcoal haemoperfusion followed by continuous venovenous hemodiafiltration. Overdose with the two drugs separately is common, but there are no reports of intoxication by simultaneous ingestion. High levels of carbamazepine and valproic acid can lead to severe systemic effects and management is made difficult by the absence of specific antidotes. Extracorporeal removal techniques are a good therapeutic option in these cases as they enhance the clearance by reducing the half-life of both drugs thereby preventing serious complications.","fulltextAvailable":false,"journal":"BMJ case reports","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Overdose","uri":{"id":"D062787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eating","uri":{"id":"D004435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidotes","uri":{"id":"D000931","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbamazepine","uri":{"id":"D002220","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consciousness","uri":{"id":"D003243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Half-Life","uri":{"id":"D006207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemodiafiltration","uri":{"id":"D017583","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25422348","title":"Overdose with antiepileptic drugs: the efficacy of extracorporeal removal techniques.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The role of zinc in seizure models and with antiepileptic drugs sodium valproate (SV) and phenytoin (PHT) was studied using experimental models of seizures in rats. Male Wistar rats, 150-250 g were administered zinc 2, 20, and 200 mg/kg, orally for 14 days. Sixty minutes after the last dose of zinc, rats were challenged with pentylenetetrazole (PTZ, 60 mg/kg, ip) or maximal electroshock (MES, 70 mA, 0.2 s duration). In another group, SV (150/300 mg/kg, ip) or PHT (40 mg/kg, ip) was administered after 30 min of zinc administration followed by seizure challenge. Zinc pretreatment at all doses had no effect on MES seizures. In PTZ seizures, with the lowest dose used, i.e., 2 mg/kg, a protective effect was observed. Neither the protection offered by the 100 % anticonvulsant dose of SV (300 mg/kg) in PTZ seizures was affected by pre-treatment with zinc nor a combination of subanticonvulsant dose of SV (150 mg/kg) and zinc offer any statistically significant advantage over either drug alone. The combination of phenytoin with zinc had no effect on any of the parameters tested. Apart from this, chronic zinc administration hampered development of chemically (PTZ)-kindled seizures in rats. Zinc supplementation is unlikely to have any undesirable effect when used in epileptics rather it may offer advantage in epileptic and seizure prone patients.","fulltextAvailable":false,"journal":"Biological trace element research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Theoretical","uri":{"id":"D008962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Wistar","uri":{"id":"D017208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Theoretical","uri":{"id":"D008962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroshock","uri":{"id":"D004597","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Zinc","uri":{"id":"D015032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pentylenetetrazole","uri":{"id":"D010433","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25422092","title":"Low Dose Zinc Supplementation Beneficially Affects Seizure Development in Experimental Seizure Models in Rats.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Expert opinion plays an important role when selecting promising clusters of chemical compounds in the drug discovery process. Indeed, experts can qualitatively assess the potential of each cluster, and with appropriate statistical methods, these qualitative assessments can be quantified into a success probability for each of them. However, one crucial element often overlooked is the procedure by which the clusters are assigned to/selected by the experts for evaluation. In the present work, the impact such a procedure may have on the statistical analysis and the entire evaluation process is studied. It has been shown that some implementations of the selection procedure may seriously compromise the validity of the evaluation even when the rating and selection processes are independent. Consequently, the fully random allocation of the clusters to the experts is strongly advocated. Copyright © 2014 John Wiley & Sons, Ltd.","fulltextAvailable":false,"journal":"Pharmaceutical statistics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Expert Testimony","uri":{"id":"D005104","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Random Allocation","uri":{"id":"D011897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Selection Bias","uri":{"id":"D015983","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bias (Epidemiology)","uri":{"id":"D015982","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cluster Analysis","uri":{"id":"D016000","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25420717","title":"Impact of selection bias on the evaluation of clusters of chemical compounds in the drug discovery process.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Rufinamide (RFD) is a novel drug that was recently approved as an adjunctive treatment for Lennox-Gastaut syndrome. Despite its reported effectiveness in generalized seizures (tonic, atonic, or tonic-clonic) in this syndrome, few data on its use in idiopathic generalized epilepsy are available. Indeed, the scientific evidence to date is limited to anecdotal cases or isolated clinical experiences. We report an uncommon, though paradigmatic, case of a woman affected by juvenile absence epilepsy (JAE) who, following a prolonged seizure-freedom period and the consequent withdrawal of valproate, presented a seizure relapse accompanied by a worsening in her electroclinical pattern. In view of this atypical evolution of JAE, characterized by drug-resistant seizures (absence and generalized tonic-clonic) and the progressive increase in electroencephalographic (EEG) abnormalities, several antiepileptic drugs were used, though to no benefit. The use of RFD instead led to a gradual control of the seizures and normalization of the EEG findings. In addition to this clinical experience, we briefly review the literature on the use of RFD in refractory generalized epilepsy.","fulltextAvailable":false,"journal":"Clinical EEG and neuroscience","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy, Generalized","uri":{"id":"D004829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy, Absence","uri":{"id":"D004832","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroencephalography","uri":{"id":"D004569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25420625","title":"Effectiveness of Rufinamide in the Treatment of Idiopathic Generalized Epilepsy With Atypical Evolution: Case Report and Review of the Literature.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The majority of toxic epidermal necrolysis (TEN) cases are provoked by \"high risk\" medications (e.g. allopurinol, aromatic anticonvulsants, nevirapine, oxicam non-steroidal anti-inflammatory agents, and sulfonamides). TEN usually occurs 1 to 8 weeks after initial administration of the offending agent, but re-administration can evoke TEN within hours to days [1]. Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal [2-4]. Herein, we report a case of hydroxychloroquine-induced fatal TEN complicated by angioinvasive Rhizopus. To our knowledge, this is the first case report of angioinvasive Rhizopus in a TEN patient. Initial misidentification of the offending agent causing TEN also serves as an important teaching point worth highlighting.","fulltextAvailable":false,"journal":"Dermatology online journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stevens-Johnson Syndrome","uri":{"id":"D013262","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nevirapine","uri":{"id":"D019829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Criminals","uri":{"id":"D057237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Allopurinol","uri":{"id":"D000493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxychloroquine","uri":{"id":"D006886","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rhizopus","uri":{"id":"D012233","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfonamides","uri":{"id":"D013449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Teaching","uri":{"id":"D013663","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25419748","title":"Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Tetracycline antibiotic drug minocycline has strongly neuroprotective and anti-inflammatory effects. Minocycline has also remarkable brain tissue penetration, is clinically entirely tolerated and properly absorbed when taken orally. In our study, we class with the effects of minocycline and chlorpromazine, a conventional antipsychotic drug, by evaluating the novelty-induced rearing, apomorphine-induced stereotypic behavior, and brain MDA levels in rats. MATERIALS AND METHODS: Four groups of rat (n = 7) were applied with minocycline (50 and 100 mg/kg, i.p.), chlorpromazine (1 mg/kg, i.p.), or isotonic saline (1 mL/kg, i.p.). One hour later, apomorphine (2 mg/kg, s.c.) was applied to each rat. RESULT: Our results showed that both doses of minocycline significantly decreased the rearing behavior in rats, whereas the decrease with chlorpromazine was higher. Minocycline also decreased the stereotypy scores in a dose-dependent manner. CONCLUSION: We concluded that minocycline has beneficial effects on rearing behavior and stereotypy, which are accepted to be indicators of antipsychotic effect. Taken together, minocycline, as an anti-oxidant and cytoprotective agent, can be useful in neuroprotection especially on early stages of psychosis or prepsychotic patients with insignificant symptoms. Minocycline is worthy of being investigated for its anti-psychotic effects as a primary or an adjunctive drug.","fulltextAvailable":false,"journal":"International journal of clinical and experimental medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Evaluation","uri":{"id":"D004341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stereotyped Behavior","uri":{"id":"D013239","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indicators and Reagents","uri":{"id":"D007202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psychotic Disorders","uri":{"id":"D011618","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salinity","uri":{"id":"D054712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apomorphine","uri":{"id":"D001058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chlorpromazine","uri":{"id":"D002746","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minocycline","uri":{"id":"D008911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stereotyping","uri":{"id":"D013240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tetracycline","uri":{"id":"D013752","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tetracyclines","uri":{"id":"D013754","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25419368","title":"Antipsychotic-like effect of minocycline in a rat model.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Both obesity and chronic inflammation are often associated with insulin resistance and type 2 diabetes. The Zucker diabetic fatty (ZDF) rat (fa/fa) is an obese animal model frequently used in type 2 diabetes research. The current study determines whether chronic administration (from 5 weeks of age through 24 weeks of age) of salsalate, a salicylate with anti-inflammatory properties, would be effective in mitigating diabetes disease progression in ZDF rats. Although a trend existed for lower blood glucose in the salsalate-treated group, significant differences were obscured by high animal-level variability. However, even in the non-drug-treated group, not all ZDF rats became diabetic as expected. Therefore, animals were parsed into two groups, regardless of drug treatment: normoglycemic ZDF rats, which maintained blood glucose profiles identical to nondiabetic Zucker lean rats (ZLRs), and hyperglycemic ZDF rats, which exhibited progressive elevation in blood glucose. To ascertain the differences between ZDF rats that became hyperglycemic and those that did not, relevant physiological indices and expression levels of adiponectin, tumor necrosis factor-α, interleukin-6, and glucocorticoid-induced leucine zipper messenger RNAs in adipose tissue were measured at sacrifice. Plasma C-reactive protein concentrations and expression levels of cytokine and glucocorticoid-induced leucine zipper messenger RNAs suggested more prevalent chronic inflammation in hyperglycemic animals. Early elevation of the insulin-sensitizing adipokine, adiponectin, was present in both ZDF groups, with the rate of its age-related decline faster in hyperglycemic animals. The most marked difference between the two groups of ZDF animals was in insulin output. Although the two ZDF populations had very similar elevated plasma insulin concentrations for the first 10 weeks, after that time, plasma insulin decreased markedly in the animals that became hyperglycemic, whereas it remained high in the normoglycemic ZDF rats. Thus, hyperglycemic ZDF animals exhibit both insulin resistance and progressive beta cell failure, whereas normoglycemic ZDF rats exhibit a lesser degree of insulin resistance that does not progress to beta cell failure. In these respects, the normoglycemic ZDF rats appear to revert back to a phenotype that strongly resembles that of nondiabetic Zucker fatty rats from which they were derived.","fulltextAvailable":false,"journal":"Diabetes, metabolic syndrome and obesity : targets and therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Proteins","uri":{"id":"D001798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Zucker","uri":{"id":"D011924","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adipose Tissue","uri":{"id":"D000273","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin Resistance","uri":{"id":"D007333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose","uri":{"id":"D001786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leucine Zippers","uri":{"id":"D016350","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin","uri":{"id":"D007328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Obesity","uri":{"id":"D009765","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thinness","uri":{"id":"D013851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adiposity","uri":{"id":"D050154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulins","uri":{"id":"D061385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leucine","uri":{"id":"D007930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salicylates","uri":{"id":"D012459","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adiponectin","uri":{"id":"D052242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adipokines","uri":{"id":"D054392","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25419150","title":"Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Though new antiepileptic drugs are emerging, approximately a third of epileptic patients still suffer from recurrent convulsions and cognitive dysfunction. Therefore, we tested whether berberine (Ber), a vegetable drug, has an anticonvulsant property and attenuates memory impairment in a pilocarpine (Pilo)-induced epilepsy model in rats. The rats were injected with 400 mg/kg Pilo to induce convulsions, and Ber 25, 50, and 100 mg/kg were administrated by the intragastric route once daily 7 days before Pilo injection until the experiment was over. Convulsions were observed after Pilo injection. For the rats that developed status epilepticus (SE), malondialdehyde, glutathione levels, superoxide dismutase, and catalase activity in the hippocampus were measured 24 hours after SE. The rats received the Morris water-maze test 2 weeks after SE, and then were killed for fluoro-jade B staining to detect the degenerating neurons. We found Ber delayed latency to the first seizure and the time to develop SE in a dose-dependent manner. Malondialdehyde levels were decreased, while glutathione and catalase activity were strengthened in Ber-injected SE rats. In the Morris water-maze test, Ber decreased escape latency compared to saline-treated SE rats. Additionally, Ber reduced the number of fluoro-jade B-positive cells in the hippocampal CA1 region. Our data suggest that Ber exerts anticonvulsant and neuroprotective effects on Pilo-induced epilepsy in rats. Simultaneously, Ber attenuates memory impairment. The beneficial effect may be partly due to mitigation of the oxidative stress burden.","fulltextAvailable":false,"journal":"Neuropsychiatric disease and treatment","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxide Dismutase","uri":{"id":"D013482","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroprotective Agents","uri":{"id":"D018696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Degeneration","uri":{"id":"D009410","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Status Epilepticus","uri":{"id":"D013226","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"CA1 Region, Hippocampal","uri":{"id":"D056547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homicide","uri":{"id":"D006708","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxides","uri":{"id":"D013481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vegetables","uri":{"id":"D014675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Berberine","uri":{"id":"D001599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catalase","uri":{"id":"D002374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glutathione","uri":{"id":"D005978","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hippocampus","uri":{"id":"D006624","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malondialdehyde","uri":{"id":"D008315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pilocarpine","uri":{"id":"D010862","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25419137","title":"Berberine exerts an anticonvulsant effect and ameliorates memory impairment and oxidative stress in a pilocarpine-induced epilepsy model in the rat.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The use of health technology assessment (HTA) to inform policy-making is established in most developed countries. Compared to licensing agencies, HTA agencies have different interests and, therefore, different evidence requirements. Criteria for coverage or reimbursement decisions on pharmaceutical compounds vary; however, it is common to include, as part of the HTA, a comparative effectiveness evaluation. This type of clinical data might go beyond that required for market authorization, thus creating an additional evidence gap between the regulatory and the reimbursement submission. The relevance of submissions to HTA agencies is consistently increasing in a pharmaceutical company's perspective, as market prospects are strongly influenced by third-party payers' coverage. In this study, we aim to describe current HTA activities with a potential impact throughout the drug development process of pharmaceuticals, with a comparative emphasis on the systems in place in Italy and in the UK. Based on an extensive literature and website review, we identified three major classes of HTA activities, beyond mainstream HTA, with the potential to influence the drug development program: 1) horizon scanning and early HTA; 2) bipartite and tripartite early dialogue between manufacturers, regulators, and HTA assessors; and 3) managed market entry agreements. From early stages of clinical research up to postauthorization studies, there is a trend toward increased collaboration between parties, anticipation of market access evidence collection, and postmarketing risk-sharing. Heterogeneity of HTA practices increases the complexity of the market access environment. Overall, there are signals that market access departments are gaining importance in the pharmaceutical companies, but there is still a lack of evidence and reporting on how the increasing relevance of HTA has reshaped the way clinical development is designed and managed.","fulltextAvailable":false,"journal":"Drug design, development and therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developing Countries","uri":{"id":"D003906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology Assessment, Biomedical","uri":{"id":"D013673","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developed Countries","uri":{"id":"D019049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance, Health, Reimbursement","uri":{"id":"D007349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Program Development","uri":{"id":"D016730","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biomedical Technology","uri":{"id":"D020811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biomedical Research","uri":{"id":"D035843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cooperative Behavior","uri":{"id":"D003299","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Licensure","uri":{"id":"D008004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mainstreaming (Education)","uri":{"id":"D008282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology","uri":{"id":"D013672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Italy","uri":{"id":"D007558","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25419117","title":"The role of health technology assessment bodies in shaping drug development.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Preclinical Research The present study was designed to evaluate the possible antinociceptive interaction between diacerhein and some antiepileptic drugs (carbamazepine, topiramate and gabapentin) on formalin-induced nociception. Diacerhein, each of the antiepileptics or a fixed dose-ratio combination of these drugs was assessed after local peripheral and oral administration in rats. lsobolographic analyses were used to define the interaction between drugs. Diacerhein, antiepileptic drugs (carbamazepine, topiramate and gabapentin) or their combinations yielded a dose-dependent antinociceptive effect when administered by both routes. Theoretical ED30 values for the combination estimated from the isobolograms were obtained as follows: diacerhein-carbamazepine (85.99 ± 7.07 μg/paw; 56.53 ± 4.56 mg/kg po), diacerhein-topiramate (197.97 ± 22.90 μg/paw; 13.06 ± 2.44 mg/kg po) and diacerhein-gabapentin (96.87 ± 17.73 μg/paw; 17.90 ± 4.70 mg/kg p.o.) for the local peripheral and oral administration routes, respectively. These values were significantly higher than the experimentally obtained ED30 values: diacerhein-carbamazepine (49.33 ± 3.37 μg/paw; 35.49 ± 7.91 mg/kg po), diacerhein-topiramate (133.00 ± 39.10 μg/paw; 8.87 ± 1.46 mg/kg po) and diacerhein-gabapentin (70.98 ± 14.73 μg/paw; 10.95 ± 3.23 mg/kg po). The combinations produced their antinociceptive effects without motor impairment in the rotarod test indicating synergistic interactions with a good side effect profile.","fulltextAvailable":false,"journal":"Drug development research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pain Measurement","uri":{"id":"D010147","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotarod Performance Test","uri":{"id":"D045442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Formaldehyde","uri":{"id":"D005557","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbamazepine","uri":{"id":"D002220","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nociception","uri":{"id":"D059225","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25418935","title":"Combination of Diacerhein and Antiepileptic Drugs After Local Peripheral, and Oral Administration in the Rat Formalin Test.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Targeting mitotic regulation is recognized as an important strategy for cancer therapy. Aurora A/B kinase and polo-like kinase 1 (PLK1) are the key mitotic regulators, and many inhibitors have been developed. Combinations of these inhibitors are anticipated to be more effective therapeutics compared with single-inhibitor treatments; however, a systematic analysis of the combined effects is lacking. Here, we constructed the first mammalian cell mitotic regulation network model, which spans from mitotic entry to anaphase initiation, and contains all key mitotic kinase targets. The combined effects of different kinase inhibitors and microtubule inhibitors were systematically explored. Simultaneous inhibition of Aurora B and PLK1 strongly induces polyploidy. Microtubule inhibitor dosage can be significantly reduced when combined with a PLK1 inhibitor. The efficacy of these inhibitor combinations was validated by our experimental results. The mitotic regulatory network model provides a platform to study the complex interactions during mitosis, enables identification of mitotic regulators, and determines targets for drug discovery research. The suggested use of combining microtubule inhibitors with PLK1 inhibitors is anticipated to enhance microtubule-inhibitor tolerance in a wide range of patients.","fulltextAvailable":false,"journal":"Molecular bioSystems","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aurora Kinase A","uri":{"id":"D064096","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aurora Kinase B","uri":{"id":"D064107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Combined Chemotherapy Protocols","uri":{"id":"D000971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microtubules","uri":{"id":"D008870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyploidy","uri":{"id":"D011123","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anaphase","uri":{"id":"D000705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitosis","uri":{"id":"D008938","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25418836","title":"Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Drug-induced liver injury [DILI] is often caused by innate and adaptive host immune responses. Characterization of inflammatory infiltrates in the liver may improve understanding of the underlying pathogenesis of DILI. AIMS: To characterize leukocytes infiltrating liver tissue from subjects with acute DILI [n = 32] vs. non-DILI causes of acute liver injury [n = 25]. METHODS: Immunostains for CD11b/CD4 (Kupffer and T helper cells), CD3/CD20 (T and B cells), and CD8/CD56 (T cytotoxic and NK cells) were evaluated in biopsies from subjects with acute DILI, either immuno-allergic [IAD] or auto-immune [AID] and idiopathic autoimmune (AIH) and viral hepatitis (VH) and correlated with clinical and pathologic features. RESULTS: All biopsies showed numerous CD8+ T cells and macrophages. DILI cases had significantly fewer B-lymphocytes than AIH and VH and significantly fewer NK cells than VH. Prominent plasma cells were unusual in IAD (3/10 cases), but were strongly associated with AIH (8/9) and also observed in most with AID (6/9). They were also found in 5/10 cases with VH. CONCLUSIONS: Liver biopsies from subjects with DILI were characterized by low counts of mature B cells and NK cells in portal triads in contrast to VH. NK cells were only found in cases of VH, whereas AIH and VH both showed higher counts of B cells than DILI. Plasma cells were most strongly associated with AIH and less so with AID, but were uncommon in IAD.","fulltextAvailable":false,"journal":"Clinical and experimental immunology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Killer Cells, Natural","uri":{"id":"D007694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adaptive Immunity","uri":{"id":"D056704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes, Helper-Inducer","uri":{"id":"D006377","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Killer Cells, Natural","uri":{"id":"D007694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis Viruses","uri":{"id":"D006518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasma Cells","uri":{"id":"D010950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Induced Liver Injury","uri":{"id":"D056486","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocytes","uri":{"id":"D001402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis","uri":{"id":"D006505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocytes","uri":{"id":"D007962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insemination, Artificial, Heterologous","uri":{"id":"D007316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insemination, Artificial, Homologous","uri":{"id":"D007317","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25418487","title":"Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Small molecule tyrosine kinase inhibitors (TKIs) are a group of highly novel and target-specific anticancer drugs. Recently, most TKIs are found to be substrates of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). However, little information is available regarding the Pgp- or BCRP-mediated interaction of TKIs with coadministered drugs/food/beverage. Our objective was to evaluate the effect of the major ingredients of grapefruit juice (GFJ), orange juice (OJ), apple juice (AJ), and green tea on P-gp and BCRP-mediated dasatinib efflux. Among the 14 ingredients screened, only tangeretin and nobiletin moderately inhibited P-gp-mediated dasatinib efflux. In contrast, four ingredients in GFJ [i.e., bergamottin, 6',7'-dihydroxybergamottin (DHB), quercetin, and kaempferol], two ingredients in OJ (tangeretin and nobiletin), and one ingredient in AJ (i.e., hesperetin) greatly inhibited BCRP-mediated dasatinib efflux at the concentration of 50 μM (p < 0.001). Further concentration-dependent studies revealed that bergamottin, DHB, tangeretin, and nobiletin are potent BCRP inhibitors, with IC50 values 3.19, 5.2, 1.19, and 1.04 μM, respectively. Further in vivo investigations are warranted to evaluate the BCRP-mediated FJ-TKI interaction. Literature reports only documented the modulatory effect of FJ and green tea on CYP3A, P-gp, and OATP. Our novel finding that FJ ingredients strongly inhibit BCRP may represent a new mechanism of beverage-drug interaction. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.","fulltextAvailable":false,"journal":"Journal of pharmaceutical sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food and Beverages","uri":{"id":"D019602","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein-Tyrosine Kinases","uri":{"id":"D011505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tyrosine","uri":{"id":"D014443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrus sinensis","uri":{"id":"D032084","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Beverages","uri":{"id":"D001628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quercetin","uri":{"id":"D011794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"P-Glycoproteins","uri":{"id":"D018435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inhibitory Concentration 50","uri":{"id":"D020128","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"P-Glycoprotein","uri":{"id":"D020168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrus paradisi","uri":{"id":"D032083","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaempferols","uri":{"id":"D044949","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochrome P-450 CYP3A","uri":{"id":"D051544","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25418056","title":"Ingredients in Fruit Juices Interact with Dasatinib Through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The efficiency of penetration of nanodrugs through cell membranes imposes further complexity due to nanothermodynamic and entropic potentials at interfaces. Action of nanodrugs is effective after cell membrane penetration. Contrary to diffusion of water diluted common molecular drugs, nanosize imposes an increasing transport complexity at boundaries and interfaces (e.g., cell membrane). Indeed, tiny dimensional systems brought the concept of \"nanothermodynamic potential,\" which is proportional to the number of nanoentities in a macroscopic system, from either the presence of surface and edge effects at the boundaries of nanoentities or the restriction of the translational and rotational degrees of freedom of molecules within them. The core element of nanothermodynamic theory is based on the assumption that the contribution of a nanosize ensemble to the free energy of a macroscopic system has its origin at the excess interaction energy between the nanostructured entities. As the size of a system is increasing, the contribution of the nanothermodynamic potential to the free energy of the system becomes negligible. Furthermore, concentration gradients at boundaries, morphological distribution of nanoentities, and restriction of the translational motion from trapping sites are the source of strong entropic potentials at the interfaces. It is evident therefore that nanothermodynamic and entropic potentials either prevent or allow enhanced concentration very close to interfaces and thus strongly modulate nanoparticle penetration within the intracellular region. In this work, it is shown that nano-sized polynuclear iron (III)-hydroxide in sucrose nanoparticles have a nonuniform concentration around the cell membrane of macrophages in vivo, compared to uniform concentration at hydrophobic prototype surfaces. The difference is attributed to the presence of entropic and nanothermodynamic potentials at interfaces.","fulltextAvailable":false,"journal":"Advances in experimental medicine and biology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Membrane","uri":{"id":"D002462","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diffusion","uri":{"id":"D004058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxides","uri":{"id":"D006878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotation","uri":{"id":"D012399","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sucrose","uri":{"id":"D013395","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanostructures","uri":{"id":"D049329","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrophobic and Hydrophilic Interactions","uri":{"id":"D057927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malpractice","uri":{"id":"D008318","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25416996","title":"Nanothermodynamics mediates drug delivery.","year":"2015"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"In the present work, some new 5-[2(3)-dialkylamino alkoxy] Indole 3-thiosemicarbazone 2-ones and 5-[2(3)-dialkylamino alkoxy] Indole 3-hydrazone 2-one were prepared from 5-hydroxy isatin. The structures of the products were characterized by IR, NMR, and MASS Spectral studies. All the compounds were examined for antiepileptic activity by maximal electroshock seizure (MES) and pentylenetetrazole (PTZ) induced convulsion method. These compounds were also evaluated for their neurotoxicity study by rotarod method. Some of these compounds showed good antiepileptic activity when compared with standard drug Phenytoin and all the compounds showed less neurotoxicity when compared with standard drug Diazepam.","fulltextAvailable":false,"journal":"Advances in experimental medicine and biology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schiff Bases","uri":{"id":"D012545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotarod Performance Test","uri":{"id":"D045442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroshock","uri":{"id":"D004597","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diazepam","uri":{"id":"D003975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indoles","uri":{"id":"D007211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isatin","uri":{"id":"D007510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pentylenetetrazole","uri":{"id":"D010433","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25416981","title":"Synthesis and Antiepileptic Activity of Schiff's Bases of Dialkylamino Alkoxy Isatin Derivatives.","year":"2015"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Traditional Chinese medicine is recently emerged as anti-cancer therapy or adjuvant with reduced side-effects and improved quality of life. In the present study, an active ingredient, 1,6,7-trihydroxyxanthone (THA), derived from Goodyera oblongifolia was found to strongly suppress cell growth and induce apoptosis in liver cancer cells. MicroRNAs are a group of small non-coding RNAs that regulate gene expression at post-transcriptional levels. Our results demonstrated that miR-218 was up-regulated and oncogene Bmi-1 was down-regulated by THA treatment. Further investigation showed that THA-induced-miR-218 up-regulation could lead to activation of tumor suppressor P16(Ink4a) and P14(ARF), the main down-stream targets of Bmi-1. In conclusion, THA might be a potential anti-cancer drug candidate, at least in part, through the activation of miR-218 and suppression of Bmi-1 expression.","fulltextAvailable":false,"journal":"Apoptosis : an international journal on programmed cell death","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine, Traditional","uri":{"id":"D008519","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Synergism","uri":{"id":"D004357","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Regulator","uri":{"id":"D005809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Neoplasms","uri":{"id":"D008113","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine, Chinese Traditional","uri":{"id":"D008516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinogens","uri":{"id":"D002273","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oncogenes","uri":{"id":"D009857","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tacrine","uri":{"id":"D013619","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25416134","title":"MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Marine actinomycetes are a potential source of a wide variety of bioactive natural products. In this work, seven pretreatments, three selective isolation media, and five artificial seawater concentrations were used to isolate actinomycetes from the sediments collected from Yellow Sea, China. Statistical analysis showed that only the isolation medium strongly affected the total and bioactive numbers of actinomycete isolates. A total of 613 actinobacterial strains were isolated and screened for antimicrobial activities; 154 isolates showed activity against at least one of nine test drug-resistant microorganisms. Eighty-nine representatives with strong antimicrobial activity were identified phylogenetically based on 16S rRNA gene sequencing, which were assigned to five different actinomycete genera Streptomyces, Kocuria, Saccharomonospora, Micromonospora, and Nocardiopsis. Using PCR-based screening for six biosynthetic genes of secondary metabolites, all 45 isolates with acute activity have at least one biosynthetic gene, 28.8 % of which possess more than three biosynthetic genes. As a case, strain SMA-1 was selected for antimicrobial natural product discovery. Three diketopiperazine dimers including a new compound iso-naseseazine B (1) and two known compounds naseseazine B (2) and aspergilazine A (3) were isolated by bioassay-guided separation. These results suggested that actinomycetes from marine sediments are a potential resource of novel secondary metabolites and drugs.","fulltextAvailable":false,"journal":"Archives of microbiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Products","uri":{"id":"D001688","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, rRNA","uri":{"id":"D020459","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Geologic Sediments","uri":{"id":"D019015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"China","uri":{"id":"D002681","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Military Personnel","uri":{"id":"D008889","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seawater","uri":{"id":"D012623","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Streptomyces","uri":{"id":"D013302","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dimerization","uri":{"id":"D019281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Actinobacteria","uri":{"id":"D039903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Micromonospora","uri":{"id":"D008847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diketopiperazines","uri":{"id":"D054659","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25416124","title":"Diversity and bioprospecting of culturable actinomycetes from marine sediment of the Yellow Sea, China.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: A large proportion of women around the world suffer from chronic diseases including mental health diseases. In the United States alone, over 12% of women of reproductive age suffer from a chronic medical condition, especially diabetes and hypertension. Chronic diseases significantly increase the odds for poor maternal and newborn outcomes in pregnant women. METHODS: A systematic review and meta-analysis of the evidence was conducted to ascertain the possible impact of preconception care for preventing and managing chronic diseases and promoting psychological health on maternal, newborn and child health outcomes. A comprehensive strategy was used to search electronic reference libraries, and both observational and clinical controlled trials were included. Cross-referencing and a separate search strategy for each preconception risk and intervention ensured wider study capture. RESULTS: Maternal prepregnancy diabetic care is a significant intervention that reduces the occurrence of congenital malformations by 70% (95% Confidence Interval (CI): 59-78%) and perinatal mortality by 69% (95% CI: 47-81%). Furthermore, preconception management of epilepsy and phenylketonuria are essential and can optimize maternal, fetal and neonatal outcomes if given before conception. Ideally changes in antiepileptic drug therapy should be made at least 6 months before planned conception. Interventions specifically targeting women of reproductive age suffering from a psychiatric condition show that group-counseling and interventions leading to empowerment of women have reported non-significant reduction in depression (economic skill building: Mean Difference (MD) -7.53; 95% CI: -17.24, 2.18; counseling: MD-2.92; 95% CI: -13.17, 7.33). CONCLUSION: While prevention and management of the chronic diseases like diabetes and hypertension, through counseling, and other dietary and pharmacological intervention, is important, delivering solutions to prevent and respond to women's psychological health problems are urgently needed to combat this leading cause of morbidity.","fulltextAvailable":false,"journal":"Reproductive health","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maternal Welfare","uri":{"id":"D008429","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women's Health","uri":{"id":"D016387","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Management","uri":{"id":"D019468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child Welfare","uri":{"id":"D002669","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mental Health","uri":{"id":"D008603","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnant Women","uri":{"id":"D037841","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Preconception Care","uri":{"id":"D016742","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perinatal Mortality","uri":{"id":"D054238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Economic Recession","uri":{"id":"D057172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fertilization","uri":{"id":"D005306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant, Newborn","uri":{"id":"D007231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Libraries","uri":{"id":"D007990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Power (Psychology)","uri":{"id":"D011209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stress, Psychological","uri":{"id":"D013315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Advance Directives","uri":{"id":"D016223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Theory of Mind","uri":{"id":"D056345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenylketonurias","uri":{"id":"D010661","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25415675","title":"Preconception care: screening and management of chronic disease and promoting psychological health.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: It is known that endothelial cells in the kidney are also strongly VEGF-dependent. Whether intravitreal drugs can be detected within the glomeruli or affect VEGF in glomerular podocytes is not known. Therefore, the aim of this pilot study was to investigate the effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. METHODS: The kidneys of eight cynomolgus monkeys, which were intravitreally injected either with 2 mg of aflibercept or with 0.5 mg of ranibizumab, were investigated one and seven days after injection. Two animals served as controls. The distribution of aflibercept, ranibizumab and VEGF was evaluated using anti-Fc- or anti-F(ab)-fragment and anti-VEGF antibodies respectively. The ratio of stained area/nuclei was calculated using a semi-quantitative computer assisted method. Glomerular endothelial cell fenestration was quantified in electron microscopy using a systematic uniform random sampling protocol and estimating the ratio of fenestrae per µm. RESULTS: Compared to the controls, the anti-VEGF stained area/nuclei ratio of the ranibizumab-treated animals showed no significant changes whereas the stained areas of the aflibercept-treated monkeys showed a significant decrease post-treatment. Immune reactivity (IR) against aflibercept or ranibizumab was detected in aflibercept- or ranibizumab treated animals respectively. The number of fenestrations of the glomerular endothelial cells has shown no significant differences except one day after aflibercept injection in which the number was increased. CONCLUSION: Surprisingly, both drugs could be detected within the capillaries of the glomeruli. After a single intravitreal injection of aflibercept, VEGF IR in the podocytes was significantly reduced compared to controls. Ranibizumab injection had no significant effect on the glomeruli's VEGF level. Whether this is caused by aflibercept's higher affinity to VEGF or because it is used in a higher stoichiometric concentration compared to ranibizumab remains to be investigated.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pilot Projects","uri":{"id":"D010865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endothelial Cells","uri":{"id":"D042783","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intravitreal Injections","uri":{"id":"D058449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macaca fascicularis","uri":{"id":"D008252","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Haplorhini","uri":{"id":"D000882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Capillaries","uri":{"id":"D002196","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney","uri":{"id":"D007668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Podocytes","uri":{"id":"D050199","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25415380","title":"Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: This article aims at determining the place of benzodiazepines in the current treatment of anxiety disorders in opposition to antidepressants, neuroleptics and anticonvulsants. Belgium and France are the only two European countries which prescribe the most benzodiazepines despite the dissuasion of the international guidelines (NICE) issued in the nineties concerning the high risk of dependance of these molecules. What about the respect of these guidelines and the use of benzodiazepines in general practice in 2014? METHODS: Review of the literature with the following key words \"anxiety disorder, benzodiazepines, anxiolytic, treatment\" in the international database of PubMed, Medline, PsycINFO, PsycARTICLES and consulting of various reference books. RESULTS: No class of molecules could measure up to benzodiazepines until now, neither from the point of view of efficiency, nor from the point of view of cost-efficiency. This is why the guidelines (NICE) discourage the few available alternatives in the general practice. International figures from Belgium and France show a continuous increase in the use of benzodiazepines in the treatment of anxiety disorders, even after the nineties. Given the fact that benzodiazepines differ from one another at the level of their action profile (graphical representation in \"stars\") and are therefore able to relieve several symptoms simultaneously, these molecules still respond nowadays to many expectations of the clinical practitioners. CONCLUSIONS: The divergence between the guidelines and the practice confirm the irreplaceability of benzodiazepines at the present time. Nevertheless, the expectation of new molecules with fewer side effects should be investigated in further research.","fulltextAvailable":false,"journal":"Psychiatria Danubina","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anxiety Disorders","uri":{"id":"D001008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reference Books","uri":{"id":"D012013","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Practice","uri":{"id":"D058006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anxiety","uri":{"id":"D001007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Books","uri":{"id":"D001877","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents","uri":{"id":"D000928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Belgium","uri":{"id":"D001530","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzodiazepines","uri":{"id":"D001569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"France","uri":{"id":"D005602","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Anxiety Agents","uri":{"id":"D014151","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25413506","title":"Role of benzodiazepines in the treatment of anxiety disorders in 2014.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Suitable laboratory methodologies for quantifying the non-vitamin K oral anticoagulants (NOAC) include liquid chromatography-tandem mass spectrometry (LC-MS/MS) or drug-calibrated assays such as the dilute thrombin time for dabigatran or anti-Xa measurements for rivaroxaban. In situations when these tests are unavailable, it has been suggested that using commercial drug calibrators on APTT and PT assays would theoretically provide reagent sensitivity to these drugs. The purpose of this study was to determine whether commercial drug calibrators deliver similar reagent sensitivity information as samples from patients receiving dabigatran or rivaroxaban as part of their routine care. Two laboratory sites tested commercial calibrator material for dabigatran and rivaroxaban (Hyphen Biomedical) using PT and APTT reagents and data was compared to samples collected from patients taking NOACs that were quantified by LC-MS/MS. Correlation statistics and calculating the amount of drug required to double the clotting time of normal plasma were performed. All drug calibrator material correlated more strongly (R2> 0.95) for any reagent/drug combination than patient samples (R2 ranged from 0.29-0.86). Dabigatran calibrator results and patient data were equivalent for SynthASil and PTT-A APTT reagents. The dabigatran and rivaroxaban calibrator material over-estimated drug sensitivity for all PT reagents when compared to sensitivity data calculated based on drug levels obtained by LC-MS/MS from patient samples. In conclusion, drug-specific calibrators overestimated reagent sensitivity which may underestimate in vivo drug concentration in a given patient. Further studies are required to assess whether this method of determining relative sensitivity of NOAC on routine coagulation assays should be recommended.","fulltextAvailable":false,"journal":"Thrombosis and haemostasis","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mass Spectrometry","uri":{"id":"D013058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin Time","uri":{"id":"D013918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calibration","uri":{"id":"D002138","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indicators and Reagents","uri":{"id":"D007202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25413383","title":"Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: IntroductionThe impact of in vitro resistance on initially appropriate antibiotic therapy (IAAT) remains unclear. We elucidated the relationship between non-IAAT and mortality, and between IAAT and multi-drug resistance (MDR) in sepsis due to Gram-negative bacteremia (GNS).MethodsWe conducted a single-center retrospective cohort study of adult intensive care unit patients with bacteremia and severe sepsis/septic shock caused by a gram-negative (GN) organism. We identified the following MDR pathogens: MDR P. aeruginosa, extended spectrum beta-lactamase and carbapenemase-producing organisms. IAAT was defined as exposure within 24 hours of infection onset to antibiotics active against identified pathogens based on in vitro susceptibility testing. We derived logistic regression models to examine a) predictors of hospital mortality and b) impact of MDR on non-IAAT. Proportions are presented for categorical variables, and median values with interquartile ranges (IQR) for continuous.ResultsOut of 1,064 patients with GNS, 351 (29.2%) did not survive hospitalization. Non-survivors were older (66.5 (55, 73.5) versus 63 (53, 72) years, P =0.036), sicker (Acute Physiology and Chronic Health Evaluation II (19 (15, 25) versus 16 (12, 19), P <0.001), and more likely to be on pressors (odds ratio (OR) 2.79, 95% confidence interval (CI) 2.12 to 3.68), mechanically ventilated (OR 3.06, 95% CI 2.29 to 4.10) have MDR (10.0% versus 4.0%, P <0.001) and receive non-IAAT (43.4% versus 14.6%, P <0.001). In a logistic regression model, non-IAAT was an independent predictor of hospital mortality (adjusted OR 3.87, 95% CI 2.77 to 5.41). In a separate model, MDR was strongly associated with the receipt of non-IAAT (adjusted OR 13.05, 95% CI 7.00 to 24.31).ConclusionsMDR, an important determinant of non-IAAT, is associated with a three-fold increase in the risk of hospital mortality. Given the paucity of therapies to cover GN MDRs, prevention and development of new agents are critical.","fulltextAvailable":false,"journal":"Critical care (London, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Care","uri":{"id":"D005791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intensive Care Units","uri":{"id":"D007362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Mortality","uri":{"id":"D017052","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intensive Care","uri":{"id":"D017055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiration, Artificial","uri":{"id":"D012121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ventilators, Mechanical","uri":{"id":"D012122","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Shock, Septic","uri":{"id":"D012772","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance, Multiple","uri":{"id":"D018432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sepsis","uri":{"id":"D018805","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physiology","uri":{"id":"D010827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ventilators, Mechanical","uri":{"id":"D012122","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ventilation","uri":{"id":"D014691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sepsis","uri":{"id":"D018805","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"beta-Lactamases","uri":{"id":"D001618","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bacteremia","uri":{"id":"D016470","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25412897","title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Enterovirus 71 (EV-A71) is a neurotropic virus that can cause severe complications involving the central nervous system. No effective antiviral therapeutics are available for treating EV-A71 infection and drug discovery efforts are rarely focused to target this disease. Thus, the main goal of this study was to discover existing drugs with novel indications that may effectively inhibit EV-A71 replication and the inflammatory cytokines elevation. In this study, we showed that LiCl, a GSK3β inhibitor, effectively suppressed EV-A71 replication, apoptosis and inflammatory cytokines production (Interleukin 6, Interleukin-1β) in infected cells. Furthermore, LiCl and an immunomodular agent were shown to strongly synergize with each other in suppressing EV-A71 replication. The results highlighted potential new treatment regimens in suppressing sequelae caused by EV-A71 replication.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antiviral Agents","uri":{"id":"D000998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukins","uri":{"id":"D007378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enterovirus","uri":{"id":"D004770","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25412347","title":"The Combination Effects of LiCl and the Active Leflunomide Metabolite, A771726, on Viral-Induced Interleukin 6 Production and EV-A71 Replication.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: UDP-galactopyranose mutase (UGM) catalyzes the interconversion between UDP-galactopyranose and UDP-galactofuranose. Absent in humans, galactofuranose is found in bacterial and fungal cell walls and is a cell surface virulence factor in protozoan parasites. For these reasons, UGMs are targets for drug discovery. Here, we report a mutagenesis and structural study of the UGMs from Aspergillus fumigatus and Trypanosoma cruzi focused on active site residues that are conserved in eukaryotic UGMs but are absent or different in bacterial UGMs. Kinetic analysis of the variants F66A, Y104A, Q107A, N207A, and Y317A (A. fumigatus numbering) show decreases in kcat/KM values of 200-1000 fold for the mutase reaction. In contrast, none of the mutations strongly affect the kinetics of enzyme activation by NADPH. These results indicate that the targeted residues are important for promoting the transition state conformation for UDP-galactofuranose formation. Crystal structures of the A. fumigatus mutant enzymes were determined in the presence and absence of UDP to understand the structural consequences of the mutations. The structures suggest important roles for Asn207 in stabilizing the closed active site, and Tyr317 in positioning of the uridine ring. Phe66 and the corresponding residue in Mycobacterium tuberculosis UGM (His68) play a role as the backstop, stabilizing the galactopyranose group for nucleophilic attack. Together, these results provide insight into the essentiality of the targeted residues for realizing maximal catalytic activity and a proposal for how conformational changes that close the active site are temporally related and coupled together.","fulltextAvailable":false,"journal":"Biochemistry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Wall","uri":{"id":"D002473","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Activation","uri":{"id":"D004789","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catalytic Domain","uri":{"id":"D020134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Activators","uri":{"id":"D020536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspergillus fumigatus","uri":{"id":"D001232","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mycobacterium tuberculosis","uri":{"id":"D009169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trypanosoma cruzi","uri":{"id":"D014349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence Factors","uri":{"id":"D037521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Galactose","uri":{"id":"D005690","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kinetics","uri":{"id":"D007700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NADP","uri":{"id":"D009249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parasites","uri":{"id":"D010271","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tuberculosis","uri":{"id":"D014376","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspergillus","uri":{"id":"D001230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mycobacterium","uri":{"id":"D009161","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trypanosoma","uri":{"id":"D014345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uridine","uri":{"id":"D014529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uridine Diphosphate","uri":{"id":"D014530","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutagenesis","uri":{"id":"D016296","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intramolecular Transferases","uri":{"id":"D019751","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eukaryota","uri":{"id":"D056890","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25412209","title":"Contributions of Unique Active Site Residues of Eukaryotic UDP-Galactopyranose Mutases to Substrate Recognition and Active Site Dynamics.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Intracellular transport of recombinant Adeno-associated virus (AAV) is still incompletely understood. In particular, the trafficking steps preceding the release of incoming AAV particles from the endosomal system into the cytoplasm-allowing subsequent nuclear import and the initiation of gene expression-remain to be elucidated fully. Others and we previously showed that a significant proportion of viral particles are transported to the Golgi apparatus, and that Golgi disruption caused by the drug brefeldin A efficiently blocks AAV2 transduction. However, because brefeldin A is known to exert pleiotropic effects on the entire endosomal system, the functional relevance of Golgi transport for AAV transduction remains to be established definitively. Here, we show that AAV2 trafficking toward the trans-Golgi network (TGN) and the Golgi apparatus correlates with transduction efficiency and relies on a non-classical retrograde transport pathway that is independent of retromer, late endosomes and recycling endosomes. AAV2 transduction is unaffected by knock-down of syntaxins 6 and 16, which are two major effectors in the retrograde transport of both exogenous and endogenous cargo. On the other hand, inhibition of syntaxin 5 function by siRNA silencing or treatment with Retro-2cycl strongly decrease AAV2 transduction and Golgi transport. This inhibition of transduction is observed with several AAV serotypes and a number of primary and immortalized cells. Together, our data strongly suggest that syntaxin 5-mediated retrograde transport to the Golgi is a broadly conserved feature of AAV trafficking that appears to be independent of the identity of the receptors used for viral attachment. IMPORTANCE: Gene therapy constitutes a promising approach for treatment of life-threatening conditions refractory to any other form of remedy. Adeno-associated virus (AAV) vectors are currently being evaluated for the treatment of diseases such as Duchenne Muscular Dystrophy, hemophilia, heart failure, Parkinson disease and others. Despite their promise as gene delivery vehicles, a better understanding of the biology of AAV-based vectors is necessary to improve further their efficacy. AAV vectors must reach the nucleus in order to deliver their genome, and their intracellular transport is not fully understood. Here, we dissect an important step of the intracellular journey of AAV by showing that retrograde transport of capsids to the trans-Golgi network is necessary for gene delivery. We show that the AAV trafficking route differs from known Golgi-targeted cargos, and we raise the possibility that this non-classical pathway is shared by most AAV variants, regardless of their attachment receptors.","fulltextAvailable":false,"journal":"Journal of virology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Failure","uri":{"id":"D006333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virion","uri":{"id":"D014771","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Therapy","uri":{"id":"D015316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dependovirus","uri":{"id":"D000229","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Golgi Apparatus","uri":{"id":"D006056","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscular Dystrophies","uri":{"id":"D009136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parkinson Disease","uri":{"id":"D010300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brefeldin A","uri":{"id":"D020126","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscular Dystrophy, Duchenne","uri":{"id":"D020388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Active Transport, Cell Nucleus","uri":{"id":"D021581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"trans-Golgi Network","uri":{"id":"D021601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Qa-SNARE Proteins","uri":{"id":"D050765","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virus Attachment","uri":{"id":"D053585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Income","uri":{"id":"D007182","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endosomes","uri":{"id":"D011992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serotyping","uri":{"id":"D012703","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Capsid","uri":{"id":"D002213","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemophilia A","uri":{"id":"D006467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Qa-SNARE Proteins","uri":{"id":"D050765","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25410859","title":"Syntaxin 5-Dependent Retrograde Transport to the Golgi is Required for AAV Transduction.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Prior event rate ratio (PERR) adjustment method has been proposed to control for unmeasured confounding. We aimed to assess the performance of the PERR method in realistic pharmacoepidemiological settings. METHODS: Simulation studies were performed with varying effects of prior events on the probability of subsequent exposure and post-events, incidence rates, effects of confounders, and rate of mortality/dropout. Exposure effects were estimated using conventional rate ratio (RR) and PERR adjustment method (i.e. ratio of RR post-exposure initiation and RR prior to initiation of exposure). RESULTS: In the presence of unmeasured confounding, both conventional and the PERR method may yield biased estimates, but PERR estimates appear generally less biased estimates than the conventional method. However, when prior events strongly influence the probability of subsequent exposure, the exposure effect from the PERR method was more biased than the conventional method. For instance, when the effect of prior events on the exposure was RR = 1.60, the effect estimate from the PERR method was RR = 1.13 and from the conventional method was RR = 2.48 (true exposure effect, RR = 2). In all settings, the variation of the estimates was larger for the PERR method than for the conventional method. CONCLUSION: The PERR adjustment method can be applied to reduce bias as a result of unmeasured confounding. However, only in particular situations, it can completely remove the bias as a result of unmeasured confounding. When applying this method, theoretical justification using available clinical knowledge for assumptions of the PERR method should be provided. Copyright © 2014 John Wiley & Sons, Ltd.","fulltextAvailable":false,"journal":"Pharmacoepidemiology and drug safety","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Dropouts","uri":{"id":"D010352","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bias (Epidemiology)","uri":{"id":"D015982","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacoepidemiology","uri":{"id":"D017891","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25410590","title":"Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Alterations in reward valuation are thought to play a central role at all stages of the addiction process. We previously reported work-aversion in an effortful T-maze task following a binge exposure to methamphetamine, and no such changes in effort following escalating doses. Limitations of the t-maze task include its two available options, with an effort requirement, in the form of increasing barrier height, varying incrementally as a function of time, and reward magnitudes held constant. Reward preferences and choices, however, are likely affected by the number of options available and the manner in which alternatives are presented. In the present experiment we investigated the long-lasting, off-drug effects of methamphetamine on reward choices in a novel effortful maze task with three possible courses of action, each associated with different effort requirements and reward magnitudes. Neuroinflammatory responses associated with drug exposure, proposed as one of the mechanisms contributing to suboptimal choices on effort-based tasks, were also examined. We investigated region-specific changes in pro- and anti-inflammatory markers in the mesocorticolimbic pathway after methamphetamine and their relationship with animals' reward choices. We observed long-lasting, increased sensitivity to differences in reward magnitude in the methamphetamine group: animals were more likely to overcome greater effort costs to obtain larger rewards on our novel effortful maze task. These behavioral changes were strongly predicted by pronounced decreases in frontocortical cytokines, but not amygdalar or striatal markers. The present results provide the first evidence that neuroinflammatory processes are associated with alterations in reward valuation during protracted drug withdrawal.Neuropsychopharmacology accepted article preview online, 20 November 2014. doi:10.1038/npp.2014.309.","fulltextAvailable":false,"journal":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reward","uri":{"id":"D012201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methamphetamine","uri":{"id":"D008694","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25409594","title":"Reductions in Frontocortical Cytokine Levels are Associated with Long-Lasting Alterations in Reward Valuation after Methamphetamine.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: NF-E2-related factor 2 (NRF2) is a transcription factor that controls the expression of a variety of antioxidant and detoxification genes. Accumulating evidence strongly suggests that NRF2 mediates cancer cell proliferation and drug resistance, as well. Single nucleotide polymorphism (SNP) -617C > A in the anti-oxidant response element-like loci of the human NRF2 gene play a pivotal role in the positive feedback loop of transcriptional activation of the NRF2 gene. Since the SNP (-617A) reportedly decreases the binding affinity to the transcription factors of NRF2/small multiple alignment format (MafK), the homozygous -617A/A allele may attenuate the positive feedback loop of transcriptional activation of the NRF2 gene and reduce the NRF2 protein level. As the consequence, cancer cells are considered to become more sensitive to therapy and less aggressive than cancer cells harboring the -617C (WT) allele. Indeed, Japanese lung cancer patients carrying SNP homozygous alleles (c. -617A/A) exhibited remarkable survival over 1,700 days after surgical operation (log-rank p = 0.021). The genetic polymorphism in the human NRF2 gene is considered as one of prognosis markers for cancer therapy.","fulltextAvailable":false,"journal":"Frontiers in genetics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Genetic","uri":{"id":"D011110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptional Activation","uri":{"id":"D015533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NF-E2-Related Factor 2","uri":{"id":"D051267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Feedback","uri":{"id":"D005246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nucleotides","uri":{"id":"D009711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lifting","uri":{"id":"D017770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25408701","title":"Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Nowadays, Cannabis sativa is considered the most extensively used narcotic. Nevertheless, this fame obscures its traditional employ in native medicine of South Africa, South America, Turkey, Egypt and in many regions of Asia as a therapeutic drug. In fact, the use of compounds containing Cannabis and their introduction in clinical practice is still controversial and strongly limited by unavoidable psychotropic effects. So, overcoming these adverse effects represents the main open question on the utilization of cannabinoids as new drugs for treatment of several pathologies. To date, therapeutic use of cannabinoid extracts is prescribed in patients with glaucoma, in the control of chemotherapy-related vomiting and nausea, for appetite stimulation in patients with anorexia-cachexia syndrome by HIV, and for the treatment of multiple sclerosis symptoms. Recently, researcher efforts are aimed to employ the therapeutic potentials of Cannabis sativa in the modulation of cannabinoid receptor activity within the central nervous system, particularly for the treatment of neurodegenerative diseases, as well as psychiatric and non-psychiatric disorders. This review evaluates the most recent available data on cannabinoids utilization in experimental and clinical studies, and highlights their beneficial effects in the prevention of the main neurological diseases and for the clinical treatment of symptoms with them correlated.","fulltextAvailable":false,"journal":"Molecules (Basel, Switzerland)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabinoid Receptor Modulators","uri":{"id":"D063385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multiple Sclerosis","uri":{"id":"D009103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"South America","uri":{"id":"D013020","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurodegenerative Diseases","uri":{"id":"D019636","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabis","uri":{"id":"D002188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"South Africa","uri":{"id":"D013019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Cannabinoid","uri":{"id":"D043882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabinoid Receptor Agonists","uri":{"id":"D063386","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa","uri":{"id":"D000349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Americas","uri":{"id":"D000569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabinoids","uri":{"id":"D002186","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sclerosis","uri":{"id":"D012598","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Advance Directives","uri":{"id":"D016223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Groups","uri":{"id":"D044382","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appetite","uri":{"id":"D001066","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asia","uri":{"id":"D001208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabis","uri":{"id":"D002188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Egypt","uri":{"id":"D004534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glaucoma","uri":{"id":"D005901","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Narcotics","uri":{"id":"D009294","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25407719","title":"Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The capability of montmorillonite as a matrix (MONT) to improve the photostability of photolabile drugs has been recently reported. Herein promethazine (PRO), which was chosen as a model drug due to its photodegradation mechanism, was intercalated into this inorganic matrix and the effects on drug photoprotection were evaluated as well. The hybrid material (MONT-PRO) was successfully prepared with high drug loading and then was characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and FT-IR spectroscopy. The spectrophotometric measurements as function of light exposure time showed that PRO intercalation into montmorillonite markedly improved the drug photostability since a five time slower degradation rate was determined compared to that measured for PRO in homogeneous solutions; ns-transient absorption measurements highlighted that the interaction with the inorganic matrix made negligible the photoionization process of the drug and its efficiency to produce singlet oxygen was strongly reduced. MONT-PRO intercalation compound could be easily formulated in gel or ointment media without losing its photostability.","fulltextAvailable":false,"journal":"Langmuir : the ACS journal of surfaces and colloids","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Ray Diffraction","uri":{"id":"D014961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry, Differential Scanning","uri":{"id":"D002152","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Design","uri":{"id":"D015195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Singlet Oxygen","uri":{"id":"D026082","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Powder Diffraction","uri":{"id":"D033362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry","uri":{"id":"D002151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen","uri":{"id":"D010100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygenators","uri":{"id":"D010106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Rays","uri":{"id":"D014965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bentonite","uri":{"id":"D001546","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercalating Agents","uri":{"id":"D007364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malpractice","uri":{"id":"D008318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photolysis","uri":{"id":"D010782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promethazine","uri":{"id":"D011398","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25407703","title":"Promethazine-Montmorillonite inclusion complex to enhance the drug photostability.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Ovarian cancer is the fifth most common cancer and the leading cause of mortality among the gynecologic cancers. Ovarian cancer is a very devastating disease it is rarely diagnosed in its early stages, and it is usually quite advanced by the time diagnosis is made leading to very poor outcomes. It is believed that in advanced stage ovarian cancer cells produce a protein that enables the tumor cells to proliferate and become resistance to conventional drug treatments. Development of new treatment options strongly relies on understanding the ovarian carcinoma ability to proliferate and to attack the cells using combination drug treatments that are synergistic. Recent studies in our laboratory have indicated that the exposure of Thymoquinone (TQ) and Epigallocatechin-3-gallate (EGCG) to adenocarcinoma of the prostate, colon, and pancreas. This study was executed to investigate the effectiveness of TQ and EGCG on reducing early stage ovarian cancer cells. A total of 72 wells were plated with (105) Caov-3 ovarian cancer cells according to standard lab protocols. Each group was subdivided into 4 groups. Group 1 served as control and groups 2, 3, and 4 were treated with TQ (16 µM), EGCG (3 µM), and TQ + EGCG, respectively. Biomarkers and morphological evaluations were performed following standard lab techniques. The results of the study revealed: (1) an increase in nitric oxide following administration of EGCG and the combination at 24 and 48 hours (p<0.05) and (2) no membrane or cellular damage to the cells at all phases. The results of this study suggest used in combination have shown to be more effective method for manipulating Caov-3 ovarian cancer cells than when used alone.","fulltextAvailable":false,"journal":"Biomedical sciences instrumentation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovarian Neoplasms","uri":{"id":"D010051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nitric Oxide","uri":{"id":"D009569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostate","uri":{"id":"D011467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostatitis","uri":{"id":"D011472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostatism","uri":{"id":"D053448","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreas","uri":{"id":"D010179","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25405443","title":"Pathophysiological Responses Associated with Exposure to TQ and EGCG Using CAOV-3 Ovarian Cancer Like Cells.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Graft-versus-host disease (GVHD) remains a common and potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation. In the skin, GVHD can present in an acute (aGVHD), chronic lichenoid or chronic sclerotic form (clGVHD, csGVHD). Measuring peripheral blood levels of the keratinocyte-derived protease inhibitor elafin has recently emerged as a promising tool for diagnosing cutaneous aGVHD. We evaluated whether the analysis of elafin expression in skin would allow distinguishing aGVHD from drug hypersensitivity rashes (DHR) and whether cutaneous elafin expression would correlate with disease severity or altered prognosis of aGVHD and clGVHD/csGVHD. Skin biopsies from aGVHD (n=22), clGVHD (n=15), csGVHD (n=7) and DHR (n=10) patients were collected and epidermal elafin expression and its association with diverse clinical/histological parameters were analyzed. Acute GVHD and DHR displayed varying degrees of elafin expression. No elafin was detectable in csGVHD, while the molecule was increased in clGVHD as compared to aGVHD. Elafin-high aGVHD/clGVHD lesions presented with epidermal thickening and were associated with poor prognosis, i.e. decreased overall survival in aGVHD and corticosteroid resistance in clGVHD. Although cutaneous elafin does not seem to discriminate aGVHD from DHR lesions, our study strongly suggests an association between cutaneous elafin expression and poor prognosis for patients with cutaneous GVHD.Journal of Investigative Dermatology accepted article preview online, 18 November 2014. doi:10.1038/jid.2014.489.","fulltextAvailable":false,"journal":"The Journal of investigative dermatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protease Inhibitors","uri":{"id":"D011480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Hypersensitivity","uri":{"id":"D004342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Graft vs Host Disease","uri":{"id":"D006086","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Hydrolases","uri":{"id":"D010447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adrenal Cortex Hormones","uri":{"id":"D000305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatology","uri":{"id":"D003880","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Elafin","uri":{"id":"D053492","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25405322","title":"Epidermal Elafin Expression is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Fusarium head blight (FHB) caused by Fusarium graminearum is a devastating disease of cereal crops worldwide. Recently, a novel fungicide JS399-19 has been launched into the marketplace to manage FHB. It is compelling that JS399-19 shows highly inhibitory activity towards some Fusarium species, but not to other fungi, indicating that it is an environmentally compatible fungicide. To explore the mode of action of this species-specific compound, we conducted a whole-genome transcript profiling together with genetic and biochemical assays, and discovered that JS399-19 targets the myosin I of F. graminearum (FgMyo1). FgMyo1 is essential for F. graminearum growth. A point mutation S217L or E420K in FgMyo1 is responsible for F. graminearum resistance to JS399-19. In addition, transformation of F. graminearum with the myosin I gene of Magnaporthe grisea, the causal agent of rice blast, also led to JS399-19 resistance. JS399-19 strongly inhibits the ATPase activity of the wild-type FgMyo1, but not the mutated FgMyo1(S217L/E420K) . These results provide us a new insight into the design of species-specific antifungal compounds. Furthermore, our strategy can be applied to identify novel drug targets in various pathogenic organisms.","fulltextAvailable":false,"journal":"Environmental microbiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Biology","uri":{"id":"D008967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Point Mutation","uri":{"id":"D017354","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnaporthe","uri":{"id":"D020082","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myosin Type I","uri":{"id":"D024461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenosine Triphosphatases","uri":{"id":"D000251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cereals","uri":{"id":"D002523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Causality","uri":{"id":"D015984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fusarium","uri":{"id":"D005670","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myosins","uri":{"id":"D009218","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnaporthe","uri":{"id":"D020082","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404531","title":"A small molecule species-specifically inhibits Fusarium myosin I.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Our aim is to review studies which assess the prevalence of sleep apneas in children with epilepsy and discuss possible mechanisms linking these two conditions, as well as the impact of sleep apneas on the prognosis of these children. METHODS: PubMed was used as the medical database source, and articles were selected and classified according to their originality, level of evidence, and relevance to the broad scope of the review. RESULTS: Children with epilepsy have a higher prevalence of sleep breathing disorders in comparison to healthy children, but this prevalence varies widely depending on the methodology of each study. Major risk factors for sleep apneas in childhood epilepsy include mainly poor seizure control and antiepileptic drug polytherapy. Indeed, epilepsy can trigger sleep apneas, as abnormal electrical discharge amplifies sleep-induced breathing instability, antiepileptic drugs disturb muscle tone, and vagus nerve stimulation modulates neurotransmission to airway muscles. On the other hand, sleep apneas enhance sleep fragmentation, thus reducing the threshold for the appearance of seizures. Moreover, they have a negative effect on the neurocognitive profile of these children, as they disturb neuroplasticity mechanisms and also have a probable association with sudden unexpected death in epilepsy. The surgical treatment of sleep apneas has been found to reduce seizure frequency, and this can offer new therapeutic choices. CONCLUSIONS: Between sleep apneas and childhood epilepsy, there is a complex relationship with reciprocal interactions. The presence of sleep apneas should be taken into account when designing the management of these children, as it creates therapeutic opportunities and limitations.","fulltextAvailable":false,"journal":"Sleep & breathing = Schlaf & Atmung","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Death, Sudden","uri":{"id":"D003645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sleep Apnea Syndromes","uri":{"id":"D012891","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sleep Deprivation","uri":{"id":"D012892","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vagus Nerve","uri":{"id":"D014630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vagus Nerve Stimulation","uri":{"id":"D055536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apnea","uri":{"id":"D001049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscles","uri":{"id":"D009132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synaptic Transmission","uri":{"id":"D009435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuronal Plasticity","uri":{"id":"D009473","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404374","title":"Sleep apneas and epilepsy comorbidity in childhood: a systematic review of the literature.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABAAβ3. Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.","fulltextAvailable":false,"journal":"Proceedings of the National Academy of Sciences of the United States of America","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Potentials","uri":{"id":"D008564","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Topoisomerase I Inhibitors","uri":{"id":"D059004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Action Potentials","uri":{"id":"D000200","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Potentials","uri":{"id":"D008564","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synaptic Transmission","uri":{"id":"D009435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autistic Disorder","uri":{"id":"D001321","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rest","uri":{"id":"D012146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synapses","uri":{"id":"D013569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synaptic Transmission","uri":{"id":"D009435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Topotecan","uri":{"id":"D019772","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404338","title":"Topoisomerase 1 inhibition reversibly impairs synaptic function.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Full-length HIV-1 RNA plays a central role in viral replication by serving as the mRNA for essential viral proteins and as the genome packaged into infectious virions. Proper RNA trafficking is required for the functions of RNA and its encoded proteins; however, the mechanism by which HIV-1 RNA is transported within the cytoplasm remains undefined. Full-length HIV-1 RNA transport is further complicated when group-specific antigen (Gag) protein is expressed, because a significant portion of HIV-1 RNA may be transported as Gag-RNA complexes, whose properties could differ greatly from Gag-free RNA. In this report, we visualized HIV-1 RNA and monitored its movement in the cytoplasm by using single-molecule tracking. We observed that most of the HIV-1 RNA molecules move in a nondirectional, random-walk manner, which does not require an intact cytoskeletal structure, and that the mean-squared distance traveled by the RNA increases linearly with time, indicative of diffusive movement. We also observed that a single HIV-1 RNA molecule can move at various speeds when traveling through the cytoplasm, indicating that its movement is strongly affected by the immediate environment. To examine the effect of Gag protein on HIV-1 RNA transport, we analyzed the cytoplasmic HIV-1 RNA movement in the presence of sufficient Gag for virion assembly and found that HIV-1 RNA is still transported by diffusion with mobility similar to the mobility of RNAs unable to express functional Gag. These studies define a major mechanism of HIV-1 gene expression and resolve the long-standing question of how the RNA genome is transported to the assembly site.","fulltextAvailable":false,"journal":"Proceedings of the National Academy of Sciences of the United States of America","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Transport","uri":{"id":"D034443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viral Proteins","uri":{"id":"D014764","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virus Replication","uri":{"id":"D014779","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Products, gag","uri":{"id":"D015683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Transport","uri":{"id":"D034443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytoplasm","uri":{"id":"D003593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diffusion","uri":{"id":"D004058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Track and Field","uri":{"id":"D014142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virion","uri":{"id":"D014771","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV-1","uri":{"id":"D015497","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Travel","uri":{"id":"D014195","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404326","title":"Cytoplasmic HIV-1 RNA is mainly transported by diffusion in the presence or absence of Gag protein.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"RATIONALE: Subanaesthetic ketamine infusion in healthy volunteers induces experiences redolent of early psychosis, including changes in the experience of one's own body. It is not clear, however, whether repeated self-administration of ketamine has a sustained effect on body representation that is comparable to that found during acute administration. OBJECTIVES: We sought to establish whether chronic ketamine use resulted in disturbances to sense of body ownership. METHODS: Following on from our work on the effects of acute ketamine infusion, we used the rubber hand illusion (RHI) to experimentally manipulate the sense of body ownership in chronic ketamine users, compared to healthy controls. RESULTS: Chronic ketamine users experienced the RHI more strongly and reported more body-image aberrations, even though they had not recently taken the drug. CONCLUSIONS: These findings suggest that the chronic ketamine model for psychosis models more long-lasting changes in sense of ownership, perhaps more akin to schizophrenia.","fulltextAvailable":false,"journal":"Psychopharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Healthy Volunteers","uri":{"id":"D064368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Body Image","uri":{"id":"D001828","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ketamine","uri":{"id":"D007649","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ownership","uri":{"id":"D010067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psychotic Disorders","uri":{"id":"D011618","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schizophrenia","uri":{"id":"D012559","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Volunteers","uri":{"id":"D014838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404087","title":"Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"This review covers the medical options for malignant gliomas based on the results of recent clinical trials and updated information on molecular markers of prognostic and predictive value. In addition to alkylating agents, the antiangiogenic drug bevacizumab is increasingly used, particularly in cases of recurrence. Supportive care, including antiedema agents, antiepileptic drugs and anticoagulants, represent complementary treatment approaches of the utmost clinical importance.","fulltextAvailable":false,"journal":"CNS drugs","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiogenesis Inhibitors","uri":{"id":"D020533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alkylating Agents","uri":{"id":"D000477","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiogenesis Inhibitors","uri":{"id":"D020533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alkylation","uri":{"id":"D000478","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alkylating Agents","uri":{"id":"D000477","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25403944","title":"Pharmacologic therapies for malignant glioma: a guide for clinicians.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: A fundamental challenge in treating disease is identifying molecular states that affect cellular responses to drugs. Here, we focus on glycogen synthase kinase 3 (GSK-3), a key regulator for many of the hallmark behaviors of cancer cells. We alter GSK-3 activity in colon epithelial cells to test its role in modulating drug response. We find that GSK-3 activity broadly affects the cellular sensitivities to a panel of oncology drugs and kinase inhibitors. Specifically, inhibition of GSK-3 activity can strongly desensitize or sensitize cells to kinase inhibitors (for example, mTOR or PLK1 inhibitors, respectively). Additionally, colorectal cancer cell lines, in which GSK-3 function is commonly suppressed, are resistant to mTOR inhibitors and yet highly sensitive to PLK1 inhibitors, and this is further exacerbated by additional GSK-3 inhibition. Finally, by conducting a kinome-wide RNAi screen, we find that GSK-3 modulates the cell proliferative phenotype of a large fraction (∼35%) of the kinome, which includes ∼50% of current, clinically relevant kinase-targeted drugs. Our results highlight an underappreciated interplay of GSK-3 with therapeutically important kinases and suggest strategies for identifying disease-specific molecular profiles that can guide optimal selection of drug treatment.","fulltextAvailable":false,"journal":"Nature chemical biology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epithelial Cells","uri":{"id":"D004847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms","uri":{"id":"D015179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen Synthase","uri":{"id":"D006006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen Synthase Kinases","uri":{"id":"D038341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen Synthase Kinase 3","uri":{"id":"D038362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen","uri":{"id":"D006003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen Synthase Kinase 3","uri":{"id":"D038362","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25402767","title":"GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The present study was designed to estimate the detailed antidiabetic activity of Pterospermum acerifolium (L.) Willd flowers. In vitro alpha amylase inhibition study was carried out on 50% ethanol extract of flowers (PAFEE) and its various fractions. The active ethyl acetate fraction (PAFEF) was subfractionated into three subfractions (PAFE1, PAFE2, and PAFE3) and subjected to acute toxicity studies followed by antidiabetic screening in vivo by streptozotocin-nicotinamide induced type II diabetes. Diabetic animals treated with PAFE2 (30 mg/kg) reduced the levels of fasting blood glucose, significantly (P < 0.001) compared to that of diabetic control animals. Histological studies on drug treated groups did not show remarkable positive changes in β-cells. PAFE2 showed 32.6 ± 1.93% glucose uptake over control and, in the presence of PI3K inhibitor wortmannin, declined to 13.7 ± 2.51%. HPLC analysis of PAFE2 reveals the presence of quercetin and apigenin as major constituents and both are inhibiting the glycogen phosphorylase enzyme in molecular modelling studies. The study evidenced strongly that the probable glucose lowering mechanism of action of active subfraction PAFE2 is by increasing the glucose uptake in peripheral tissues and by inhibition of gluconeogenesis.","fulltextAvailable":false,"journal":"BioMed research international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"alpha-Amylases","uri":{"id":"D000516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose","uri":{"id":"D001786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Molecular","uri":{"id":"D008958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen Phosphorylase","uri":{"id":"D024981","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle Cells","uri":{"id":"D032342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetals","uri":{"id":"D000080","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetates","uri":{"id":"D000085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fasting","uri":{"id":"D005215","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoglycemic Agents","uri":{"id":"D007004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscles","uri":{"id":"D009132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethanol","uri":{"id":"D000431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amylases","uri":{"id":"D000681","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gluconeogenesis","uri":{"id":"D005943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycogen","uri":{"id":"D006003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylases","uri":{"id":"D006005","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quercetin","uri":{"id":"D011794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flowers","uri":{"id":"D035264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apigenin","uri":{"id":"D047310","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25401101","title":"Antidiabetic Activity of Pterospermum acerifolium Flowers and Glucose Uptake Potential of Bioactive Fraction in L6 Muscle Cell Lines with Its HPLC Fingerprint.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: An automated multi-analyte screening method for the identification and quantification of 92 drugs and metabolites based on on-line solid-phase extraction-high-performance liquid chromatography-diode array detection technique was developed and successfully validated. In addition, a database with 870 entries including UV-spectra, relative/retention times and response factors of toxicologically relevant compounds was created. Plasma samples (0.2 mL) were treated with methanol, diluted with buffer and on-line extracted (Strata X, 20 ×2 mm, 25 µm) at pH 9. Analytical separation was carried out on a Gemini NX column (150 ×4.6 mm, 3 µm) using gradient elution with acetonitrile-water (90:10,v/v) and 0.05 m potassium dihydrogen phosphate buffer (pH 2.3). Linear calibration curves with correlation coefficients ≥0.9950 were obtained for 78 analytes. As an additional benefit, the newly developed method allows the quantification of 42 analytes (e.g. antidepressants, neuroleptics and anticonvulsants) in a concentration range suitable for therapeutic drug monitoring. Limits of quantitation ranged from 0.02 mg/L (chlordiazepoxide) to 3.4 mg/L (mexiletine). Inter- and intra-day precisions of quality control samples (low/high) were better than 15% (zolpidem) and accuracy (bias) ranged from -11% (opipramol, venlafaxine) to 11% (venlafaxine, trazodone). Tests for carry-over and sample stability under different storage conditions were also performed and stability was adequate. Four cases of poisoning analysis are presented. Copyright © 2014 John Wiley & Sons, Ltd.","fulltextAvailable":false,"journal":"Biomedical chromatography : BMC","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Control","uri":{"id":"D011786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methanol","uri":{"id":"D000432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calibration","uri":{"id":"D002138","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen-Ion Concentration","uri":{"id":"D006863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphates","uri":{"id":"D010710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Potassium","uri":{"id":"D011188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bias (Epidemiology)","uri":{"id":"D015982","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents","uri":{"id":"D000928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chlordiazepoxide","uri":{"id":"D002707","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mexiletine","uri":{"id":"D008801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Opipramol","uri":{"id":"D009888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trazodone","uri":{"id":"D014196","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25400270","title":"Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of basic drugs and metabolites.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To characterize the clinical characteristics of drug hypersensitivity syndrome (DHS). METHODS: The clinical characteristics of 10 DHS patients admitted into our hospital were analyzed retrospectively. And the occurrence patterns of DHS were summarized. RESULTS: There were 4 males and 6 females with an age range of 17 to 66 years. Suspected drugs were anticonvulsants (n = 5), allopurinol (n = 2), antibiotics (n = 1), acetaminophen (n = 1) and unknown (n = 1). All cases developed skin rashes with fever within 14 to 60 days (n = 10). Lymphadenopathy was observed (n = 6). Morbilliform eruption was most common skin rash (n = 6); facial swelling was also appeared (n = 7). Eosinophilia was observed in all cases (n = 10). Liver involvement was common (n = 9). Autoimmune antibodies abnormality was uncommon; viral infection was complication in several cases. Glucocorticoids were applied in all cases (n = 10), 3 severe cases were administrated with intravenous immunoglobulin (IVIg). The clinical outcomes included discharging with recovery (n = 7), later diagnosed of non-Hodgkin lymphoma (n = 2) and in-hospital death (n = 1). CONCLUSIONS: The clinical manifestations of DHS are complicated. And the common reactive drugs include anticonvulsants, allopurinol, antiinflammatory drugs and antibiotics. Some cases may be misdiagnosed and long-term follow-ups are required.","fulltextAvailable":false,"journal":"Zhonghua yi xue za zhi","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Intravenous","uri":{"id":"D061605","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Hypersensitivity","uri":{"id":"D004342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exanthema","uri":{"id":"D005076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma, Non-Hodgkin","uri":{"id":"D008228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins, Intravenous","uri":{"id":"D016756","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Hypersensitivity Syndrome","uri":{"id":"D063926","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnostic Errors","uri":{"id":"D003951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eosinophilia","uri":{"id":"D004802","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucocorticoids","uri":{"id":"D005938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphatic Diseases","uri":{"id":"D008206","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma","uri":{"id":"D008223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetaminophen","uri":{"id":"D000082","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Allopurinol","uri":{"id":"D000493","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25399980","title":"[Clinical characteristics of drug hypersensitivity syndrome in 10 patients].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: The longterm use of tumor necrosis factor (TNF)-α blockers is limited by the formation of neutralizing antibodies. To the best of our knowledge, immunogenicity in psoriatic arthritis (PsA) has not been investigated in depth. Our objective was to evaluate the prevalence and significance of TNF-α blocker immunogenicity in PsA. METHODS: Consecutive patients with PsA treated with either infliximab (IFX), adalimumab (ADA), or etanercept (ETN) > 3 months participated in our cross-sectional study. Their demographic and clinical characteristics, skin and joint disease activity, and records of use of methotrexate (MTX) and other medications were collected. Drug levels (ELISA) and antidrug antibodies (ADAb; Bridging ELISA) were evaluated before the next injection or infusion. RESULTS: A total of 93 patients with PsA were recruited (48 receiving ADA, 24 IFX, and 21 ETN), with a mean age of 53 years (range 21-83 yrs), composed of 53% women. One-fourth of the patients were concomitantly treated with MTX. Altogether, 77% of the patients demonstrated therapeutic drug levels. High levels of ADAb were found in 29% of patients taking ADA, 21% taking IFX, and 0% taking ETN. ADAb significantly correlated with lower drug levels, higher 28-joint Disease Activity Scores, and higher global assessments. MTX use correlated significantly with a lower prevalence of ADAb. CONCLUSION: Significant levels of ADAb were present in up to 29% of patients with PsA treated with ADA or IFX. ADAb clearly correlated with low therapeutic drug levels and higher disease activity variables. The use of MTX significantly decreased ADAb prevalence, and its use should be strongly considered in combination with TNF-α blocker antibodies in patients with PsA.","fulltextAvailable":false,"journal":"The Journal of rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factors","uri":{"id":"D048069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Joint Diseases","uri":{"id":"D007592","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Psoriatic","uri":{"id":"D015535","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Neutralizing","uri":{"id":"D057134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25399390","title":"Prevalence of TNF-α Blocker Immunogenicity in Psoriatic Arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Toxic epidermal necrolysis (TEN) is a severe drug induced type IV hypersensitivity syndrome that can be caused by anticonvulsant drugs, especially the aromatic anticonvulsants such as phenytoin. Most patients with brain metastasis receive whole brain radiotherapy along with anti-edema measures and anticonvulsants either as prophylactic or for symptom control; phenytoin being the most commonly used drug. In a subset of patients, cranial irradiation may act as a precipitating factor along with anticonvulsants for the development of TEN. We report a 54-year-old patient with metastatic non-small cell lung cancer  treated with palliative whole brain and mediastinal radiotherapy with concurrent phenytoin-developing TEN, which started within the radiation portals with subsequent generalization. Though a rare, but serious complication, avoidance of the use of phenytoin concurrent with radiotherapy, replacing phenytoin with newer anticonvulsants, early recognition, aggressive management and awareness of this possible complication has been implied upon in this report. ","fulltextAvailable":false,"journal":"Saudi medical journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity, Delayed","uri":{"id":"D006968","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stevens-Johnson Syndrome","uri":{"id":"D013262","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Precipitating Factors","uri":{"id":"D015985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cranial Irradiation","uri":{"id":"D016371","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thorax","uri":{"id":"D013909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Generalization (Psychology)","uri":{"id":"D005793","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mediastinitis","uri":{"id":"D008480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25399219","title":"Toxic epidermal necrolysis in a patient receiving concurrent phenytoin and whole brain and thoracic radiotherapy.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: In Mekong Delta farms (Vietnam) antimicrobials are extensively used, but limited data are available on levels of antimicrobial resistance (AMR) among Escherichia coli. We performed a structured survey of AMR in E. coli (n=434) from 90 pig, chicken and duck farms. Results were compared with AMR among E. coli (n=234) from 66 small wild animals (rats and shrews) trapped on farms/forests/rice fields. Isolates were susceptibility-tested against eight antimicrobials. E. coli isolates from farmed animals were resistant against (median) 4 [IQR 3-6] antimicrobials, vs. 1 [IQR 1-2] among wild mammal isolates (p<0.001). The prevalence of AMR among farmed species isolates (vs. wild animals) was: tetracycline 84.7% (vs. 25.6%), ampicillin 78.9% (vs. 85.9%), trimethoprim/sulphamethoxazole 52.1% (vs. 18.8%), chloramphenicol 39.9% (vs. 22.5%), amoxicillin/clavulanic acid 36.6% (vs. 34.5%) and ciprofloxacin 24.9% (vs. 7.3%). Prevalence of multi-drug resistance (MDR) (resistance against three or more antimicrobial classes) among pig isolates was 86.7%, compared with 66.9 - 72.7% among poultry isolates. After adjusting for host species, MDR was ∼8 times greater among isolates from wild mammals trapped on farms than in forests/rice fields (p<0.001). Isolates were assigned to a unique profile representing their combination of susceptibility results. Multivariable analysis of variance indicated that AMR profiles from wild mammals trapped on farms and domestic animals were more alike (R(2) range=0.14 - 0.30) compared with E. coli from domestic animals and mammals trapped in the wild (R(2) range 0.25 - 0.45). Results strongly suggest that AMR on farms is a key driver of environmental AMR in the Mekong Delta.","fulltextAvailable":false,"journal":"Applied and environmental microbiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analysis of Variance","uri":{"id":"D000704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analysis of Variance","uri":{"id":"D000704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals, Domestic","uri":{"id":"D000829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia coli","uri":{"id":"D004926","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals, Wild","uri":{"id":"D000835","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clavulanic Acids","uri":{"id":"D002969","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance, Multiple","uri":{"id":"D018432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clavulanic Acid","uri":{"id":"D019818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amoxicillin-Potassium Clavulanate Combination","uri":{"id":"D019980","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia","uri":{"id":"D004925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mammals","uri":{"id":"D008322","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfamethoxazole","uri":{"id":"D013420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trees","uri":{"id":"D014197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vietnam","uri":{"id":"D014744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Livestock","uri":{"id":"D058751","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amoxicillin","uri":{"id":"D000658","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ampicillin","uri":{"id":"D000667","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chloramphenicol","uri":{"id":"D002701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ciprofloxacin","uri":{"id":"D002939","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Poultry","uri":{"id":"D011200","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tetracycline","uri":{"id":"D013752","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tetracyclines","uri":{"id":"D013754","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trimethoprim","uri":{"id":"D014295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clavulanic Acid","uri":{"id":"D019818","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25398864","title":"High levels of antimicrobial resistance among Escherichia coli isolates from livestock farms and synanthropic rats and shrews in the Mekong Delta of Vietnam.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Metastasis from solid tumours is associated with significant morbidity and mortality, and is the leading cause of cancer-related deaths. Voltage-gated sodium channels (VGSCs) are drug targets for the treatment of epilepsy. VGSCs are also present in cancer cells, where they regulate metastatic cell behaviours, including cellular movement and invasion. Treating cancer cells with the VGSC-inhibiting anticonvulsant phenytoin reduces cellular invasion and migration. Together, these suggest that VGSCs may be useful targets for inhibiting metastasis. The purpose of this study is to test the hypothesis that use of VGSC-inhibiting drugs will reduce metastasis, and therefore increase survival time in patients with cancer. METHODS AND ANALYSIS: A cohort study based on primary care data from the QResearch database will include patients with one of the three common tumours: breast, bowel and prostate. The primary outcome will be overall survival from the date of cancer diagnosis. Cox proportional hazards regression will be used to compare the survival of patients with cancer taking VGSC-inhibiting drugs (including anticonvulsants and class I antiarrhythmic agents) with patients with cancer not exposed to these drugs, adjusting for age and sex. Exposure to VGSC-inhibiting drugs will be defined as having at least one prescription for these drugs prior to cancer diagnosis. High and low exposure groups will be identified based on the length of use. A number of sensitivity and secondary analyses will be conducted. ETHICS AND DISSEMINATION: The protocol has been independently peer-reviewed and approved by the QResearch Scientific Board. The project has also been approved by the University of York Ethical Review Process. The results will be presented at international conferences and published in an open access peer-reviewed journal, in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria.","fulltextAvailable":false,"journal":"BMJ open","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cause of Death","uri":{"id":"D002423","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proxy","uri":{"id":"D019727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primary Health Care","uri":{"id":"D011320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Channels","uri":{"id":"D015222","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethical Review","uri":{"id":"D026724","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Voltage-Gated Sodium Channels","uri":{"id":"D061566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Arrhythmia Agents","uri":{"id":"D000889","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostate","uri":{"id":"D011467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostatitis","uri":{"id":"D011472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Journalism","uri":{"id":"D020452","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostatism","uri":{"id":"D053448","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemiology","uri":{"id":"D004813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25398679","title":"Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The use of intermittent preventive treatment in pregnant women (IPTp), children (IPTc) and infant (IPTi) is an increasingly popular preventive strategy aimed at reducing malaria risk in these vulnerable groups. Studies to understand how this preventive intervention can affect the spread of anti-malarial drug resistance are important especially when there is human movement between neighbouring low and high transmission areas. Because the same drug is sometimes utilized for IPTi and for symptomatic malaria treatment, distinguishing their individual roles on accelerating the spread of drug resistant malaria, with or without human movement, may be difficult to isolate experimentally or by analysing data. A theoretical framework, as presented here, is thus relevant as the role of IPTi on accelerating the spread of drug resistance can be isolated in individual populations and when the populations are interconnected and interact. METHODS: A previously published model is expanded to include human movement between neighbouring high and low transmission areas, with focus placed on the malaria parasites. Parasite fitness functions, determined by how many humans the parasites can infect, are used to investigate how fast resistance can spread within the neighbouring communities linked by movement, when the populations are at endemic equilibrium. RESULTS: Model simulations indicate that population movement results in resistance spreading fastest in high transmission areas, and the more complete the anti-malarial resistance the faster the resistant parasite will tend to spread through a population. Moreover, the demography of infection in low transmission areas tends to change to reflect the demography of high transmission areas. Additionally, when regions are strongly connected the rate of spread of partially resistant parasites (R1) relative to drug sensitive parasites (RS), and fully resistant parasites (R2) relative to partially resistant parasites (R1) tend to behave the same in both populations, as should be expected. CONCLUSIONS: In fighting anti-malarial drug resistance, different drug resistance monitoring and management policies are needed when the area in question is an isolated high or low transmission area, or when it is close and interacting with a neighbouring high or low transmission area, with human movement between them.","fulltextAvailable":false,"journal":"Malaria journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnant Women","uri":{"id":"D037841","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antimalarials","uri":{"id":"D000962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malaria","uri":{"id":"D008288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parasites","uri":{"id":"D010271","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Residence Characteristics","uri":{"id":"D012111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antimalarials","uri":{"id":"D000962","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25398463","title":"The effect of intermittent preventive treatment on anti-malarial drug resistance spread in areas with population movement.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Current drugs against HIV can suppress the progression to AIDS but cannot clear the patient from the virus. Because of potential side effects of these drugs and the possible development of drug resistance, finding a cure for HIV infection remains a high priority of HIV/AIDS research. We recently generated a recombinase (termed Tre) tailored to efficiently eradicate the provirus from the host genome of HIV-1 infected cells by specifically targeting a sequence that is present in the long terminal repeats (LTRs) of the viral DNA [1]. In vivo analyses in HIV-infected humanized mice demonstrated highly significant antiviral effects of Tre recombinase [2]. However, the fact that Tre recognizes a particular HIV-1 subtype A strain may limit its broad therapeutic application. To advance our Tre-based strategy towards a universally efficient cure, we have engineered a new, universal recombinase (uTre) applicable to the majority of HIV-1 infections by the various virus strains and subtypes. We employed the search tool SeLOX [3] in order to find a well-conserved HIV-1 proviral sequence that could serve as target site for a universal Tre from sequences compiled in the Los Alamos HIV Sequence Database. We selected a candidate (termed loxLTRu) with a mean conservation rate of 94% throughout the major HIV-1 subtype groups A, B and C. We applied loxLTRu as substrate in our established substrate-linked protein evolution (SLiPE) process [4] and evolved the uTre recombinase in 142 evolution cycles. Highly specific enzymatic activity on loxLTRu is demonstrated for uTre in both Escherichia coli and human cells. Naturally occurring viral variants with single mutations within the loxLTRu sequence are also shown to be efficiently targeted by uTre, further increasing the range of applicability of the recombinase. Potential off-target sites in the human genome are not recombined by uTre. Furthermore, uTre expression in primary human T cells shows no obvious Tre-related cytopathic or genotoxic effects. Finally, uTre expressing mice show no undesired phenotypes during their normal lifespan. We have developed a broad-range HIV-1 LTR specific recombinase that has the potential to be effective against the vast majority of HIV-1 strains and to cure HIV-1 infected cells from the infection. These results strongly encouraged us in our confidence that a Tre recombinase-mediated HIV eradication strategy may become a valuable component of a future therapy for HIV-infected patients.","fulltextAvailable":false,"journal":"Journal of the International AIDS Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA, Viral","uri":{"id":"D004279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia coli","uri":{"id":"D004926","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV Infections","uri":{"id":"D015658","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome, Human","uri":{"id":"D015894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV Long Terminal Repeat","uri":{"id":"D016325","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Terminal Repeat Sequences","uri":{"id":"D020079","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antiviral Agents","uri":{"id":"D000998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Viruses","uri":{"id":"D004267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia","uri":{"id":"D004925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombination, Genetic","uri":{"id":"D011995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV-1","uri":{"id":"D015497","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acquired Immunodeficiency Syndrome","uri":{"id":"D000163","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proviruses","uri":{"id":"D011533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Untranslated Regions","uri":{"id":"D020506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombinases","uri":{"id":"D045522","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25397454","title":"Universal Tre (uTre) recombinase specifically targets the majority of HIV-1 isolates.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Despite plasma levels of certain HIV drugs decreasing in the third trimester of pregnancy there is no definitive evidence that therapeutic drug monitoring (TDM) improves HIV control and prevents mother-to-child transmission (MTCT). Indeed \"one-off\" TDM measurements are thought to poorly correlate with overall drug exposure [1]. We aim to describe baseline demographic and clinical characteristics of pregnant women with HIV, and to compare their HIV control, management during pregnancy and neonatal outcomes with respect to whether TDM was performed. MATERIALS AND METHODS: Retrospective cross-sectional case note analysis was performed on pregnant women with HIV who attended North Manchester General Hospital and Manchester Royal Infirmary from 1st January 2008 to 28th May 2013. RESULTS: A total of 171 pregnancies were included; 39% (n=66) had TDM. The majority of patients were of African origin (85%) and age range was 16-42 years (median 32 years). TDM was found to be associated with a history of poor adherence to therapy (TDM 23%, vs no TDM 10%, p=0.017), although baseline viral load (VL) and CD4 counts were comparable between TDM and non-TDM groups (p=0.4756 and 0.9492, respectively). TDM was also associated with protease inhibitors (PI) (TDM 94% vs no TDM 77%, p= 0.004). Within the PI group, TDM was more strongly associated with atazanavir use than other PI's (55%, p=0.023). TDM was not associated with any other demographic variable or with either of the two hospital sites (p=0.427). TDM was associated with medication alterations during pregnancy (TDM 67% vs no TDM 13%, p=0.052), but was not associated with any difference in outcomes with similar proportions of newly detectable VL during pregnancy (TDM 12% vs no TDM 7%, p=0.220) and VL detectable at birth (TDM 14% vs no TDM 9%, p= 0.293). There were no instances of MTCT. CONCLUSIONS: TDM was associated with PI use and a history of poor adherence at baseline. TDM was not associated with improved HIV control during pregnancy and there was no MTCT. TDM was not shown to have any additional benefit in pregnancy and its routine use is not recommended to improve HIV control or reduce MTCT.","fulltextAvailable":false,"journal":"Journal of the International AIDS Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Trimester, Third","uri":{"id":"D011263","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Trimesters","uri":{"id":"D011264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnant Women","uri":{"id":"D037841","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protease Inhibitors","uri":{"id":"D011480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"CD4 Lymphocyte Count","uri":{"id":"D018791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viral Load","uri":{"id":"D019562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnant Women","uri":{"id":"D037841","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, General","uri":{"id":"D006769","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Trimester, Third","uri":{"id":"D011263","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant, Newborn","uri":{"id":"D007231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Hydrolases","uri":{"id":"D010447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25397445","title":"The use of TDM in pregnant HIV-positive women: a retrospective cross-sectional review of five years practice in two large hospitals in Manchester.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: In 2013, the World Health Organization (WHO) recommended scaling up of routine viral load (VL) monitoring for patients on antiretroviral therapy (ART) in resource-limited settings [1]. During the transition phase from no VL-testing at all to routine VL-monitoring, targeted VL for groups at particular risk of virologic failure (VF) may be an option [2]. We present socio-demographic and clinical risk factors for VF in a cohort in rural Lesotho with no access to VL prior to the study. MATERIALS AND METHODS: Data derive from a cross-sectional study providing multi-disease screening as well as VL testing to adult patients (≥16 years old) on first-line ART ≥6 months [3]. VF was defined as VL≥1000 copies/mL. Assessed potential predictors of VF were: (1) socio-demographic (sex, age, wealth-quintile, education, employment status, disclosure of HIV status to environment, travel-time to facility); (2) treatment history (history of treatment interruption >2 days, previous drug substitution within first-line ART, time on ART, ART-base and -backbone); (3) adherence (pill count) and (4) clinical (clinical or immunological failure as defined by WHO guidelines [1], presence of papular pruritic eruption (PPE)). All variables with association to VF in univariate analysis were included in a multivariate logistic regression reporting adjusted Odds ratios (aOR). RESULTS: Data from 1,488 patients were analyzed. Overall VF-prevalence was 6.9% (95% CI 5.7-8.3). In univariate analysis, the following were associated with VF: age <30, lower wealth-quintile, no primary education, history of treatment interruption, nevirapine-base, zidovudine-backbone, history of drug substitution, travel-time to clinic ≥2 hours, disclosure of HIV status to <5 persons, clinical failure, presence of PPE and immunological failure. In multivariate analysis, 6 out of the above 12 variables were independent predictors: age <30 years (aOR: 2.4; 95% CI 1.1-5.3, p=0.029), history of treatment interruption (2.5; 1.3-4.7, p=0.005), PPE (6.9; 2.5-18.9, p<0.001), immunological failure (11.5; 5.7-23.2, p<0.001), history of drug substitution (1.9; 1.0-3.7, p=0.043), disclosure of HIV status to <5 persons (1.8; 1.1-3.1, p=0.03). CONCLUSION: In this cohort in rural Lesotho, several socio-demographic and clinical predictors were associated with VF. Particularly age <30 years, history of treatment interruption, PPE and immunological failure were strongly associated with VF. These patients may be prioritized for targeted VL-testing.","fulltextAvailable":false,"journal":"Journal of the International AIDS Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Educational Status","uri":{"id":"D004522","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monitoring, Physiologic","uri":{"id":"D008991","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viral Load","uri":{"id":"D019562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa, Southern","uri":{"id":"D000353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Employment","uri":{"id":"D004651","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health","uri":{"id":"D014943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Substitution","uri":{"id":"D057915","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa","uri":{"id":"D000349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lesotho","uri":{"id":"D007927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disclosure","uri":{"id":"D030881","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25397416","title":"Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Aim: the authors aimed to show the possible relationship between the keratoconjunctivitis sicca (KCS) and Chlamydia pneumonia from the point of view of clinical and microbiological diagnostic. Material and Methods: 94 adult patients were treated for follicular conjunctivitis with symptoms of KCS with possible Chlamydia pneumoniae etiology. The diagnosis of a chlamydial infection based on the serological positivity of chlamydia antibodies and further based on the antigen positivity in conjunctival imprint preparations. Patients were treated with azithromycin for a period of 12 days. Results: The reciprocal relationship between chlamydial infection and ocular symptoms was proved at 21 patients (22%). 90% of patients showed positive anti-Chlamydia pneumoniae IgA and/or IgM with positivity in 80%, including anti-LSP IgA and/or IgM antibodies. This finding was in correlation with the medium to strongly positive finding of anti-cHSP60 IgG. In two patients this infection was confirmed by the positivity of Chlamydia pneumoniae DNA in peripheral leucocytes. The test group (100 healthy persons) showed 69% negative finding of anti-Chlamydia pneumoniae antibodies or only positive anamnestic antibodies (IgG) and 31% positive antibodies IgA or IgM without clinical sings. Conclusion: This study indicated the possible relationship between KCS and Chlamydia pneumoniae in the course of simultaneous clinical signs of follicular conjunctivitis. KCS is a consequence of the action of local infection at the surface of the conjunctiva. It also indicated the necessity of simultaneous evaluation of microbiological findings and the clinical picture in consideration of overall antibiotic treatment in view of the high antibody background of Chlamydia pneumoniae in the adult population in the Czech Republic. The authors aimed to show the possible relationship between the keratoconjunctivitis sicca and Chlamydia pneumoniae based on results of two studies.Some patents on conjunctivitis are also briefly described in this article.","fulltextAvailable":false,"journal":"Recent patents on inflammation & allergy drug discovery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eye Infections","uri":{"id":"D015817","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Keratoconjunctivitis Sicca","uri":{"id":"D007638","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chlamydophila pneumoniae","uri":{"id":"D016993","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Czech Republic","uri":{"id":"D018153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctiva","uri":{"id":"D003228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctivitis","uri":{"id":"D003231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pneumonia","uri":{"id":"D011014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin A","uri":{"id":"D007070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin M","uri":{"id":"D007075","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Keratoconjunctivitis","uri":{"id":"D007637","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Azithromycin","uri":{"id":"D017963","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Singing","uri":{"id":"D063346","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25395268","title":"The Role of Chlamydia Pneumoniae in the Etiology Keratoconjunctivitis Sicca (KCS).","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: A simple gas chromatographic method with mass spectrometry detection was developed and validated for the determination of lacosamide in human plasma. Lacosamide and the internal standard, levetiracetam-d6 , were extracted from 200 μL plasma, by a solid-phase extraction through HF Bond Elut C18 columns, and derivatized using N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide with 1% tert-butyldimethylsilylchloride in acetonitrile. The limit of quantification was found to be 0.20 μg/mL and the assay was linear up to 20.0 μg/mL with correlation coefficient ≥0.994. The intra- and inter-day precision values were less than 4.1% in terms of% relative standard deviation and the values of intra- and inter-day accuracy were found to be within -7.2 and 5.3% in terms of% relative error. Absolute recovery of the method for lacosamide was determined at three concentration levels and ranged from 92.5-97.6%. The developed method uses small volumes of plasma and proved to be simple, rapid and sensitive for the determination of lacosamide in plasma. This method can be used in routine every day analysis of plasma samples obtained from patients that follow respective antiepileptic treatment and for the investigation of clinical and forensic cases where lacosamide is involved. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"Journal of separation science","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gas Chromatography-Mass Spectrometry","uri":{"id":"D008401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasma Volume","uri":{"id":"D010953","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mass Spectrometry","uri":{"id":"D013058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, Gas","uri":{"id":"D002849","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography","uri":{"id":"D002845","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetonitriles","uri":{"id":"D000097","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25395063","title":"A fully validated method for the determination of lacosamide in human plasma using gas chromatography with mass spectrometry. Application for therapeutic drug monitoring.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Valproate (VPA) is a widely used antiepileptic drug - also in the elderly. A female patient was diagnosed with epilepsy at the age of 60 years and treated with VPA for 16 years before developing tremor, rigidity, cognitive impairment and descending consciousness progressing to coma. After discontinuation of VPA she regained full consciousness, could talk and feed herself. The extrapyramidal and cognitive symptoms completely subsided during the following months. VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment.","fulltextAvailable":false,"journal":"Ugeskrift for laeger","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurobehavioral Manifestations","uri":{"id":"D019954","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consciousness","uri":{"id":"D003243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minoxidil","uri":{"id":"D008914","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25394838","title":"[Valproate can induce reversible encephalopathy.]","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50-60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance. METHODS: We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino-TMZ). RESULTS: GNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino-TMZ, p < 0.0071 compared to Irino-TMZ alone). CONCLUSIONS: Our data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino-TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.","fulltextAvailable":false,"journal":"Cancer chemotherapy and pharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Nude","uri":{"id":"D008819","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Growth Factors","uri":{"id":"D009414","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain-Derived Neurotrophic Factor","uri":{"id":"D019208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Foundations","uri":{"id":"D005582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain-Derived Neurotrophic Factor","uri":{"id":"D019208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroblastoma","uri":{"id":"D009447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tropomyosin","uri":{"id":"D014335","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inhibitory Concentration 50","uri":{"id":"D020128","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25394774","title":"TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Several genetic single nucleotide polymorphisms (SNPs) in biotransformation enzymes (CYP3A4, CYP3A5) or transporter proteins (multidrug resistance MDR1 gene product, P-gp) are involved in PI metabolism so that PI pharmacokinetics is characterized by a large inter-individual variability. The aim of this study was: (i) to develop an in-house PCR/direct sequencing, based on DNA purification of full-length CYP3A4 and CYP3A5 genes (SNPs) and MDR1 C3435T variant; (ii) to investigate association of CYP3A4 and CYP3A5 reported or unreported genetic polymorphisms and MDR1-C3435T (CC homozygote, CT heterozygote, TT homozygote) with clinical outcome of HIV-1 infected subjects treated with PI. METHODS: Overall, 39 HIV-1 infected patients receiving boosted Lopinavir (LPV/r) monotherapy after virological suppression were genotyped and analyzed through PCR and direct sequencing of full-length CYP3A4 and CYP3A5 gene sequences (1) and MDR1 gene (C3435T). CD4+T-cell counts and plasma viral load were analyzed before and after LPV/r initiation; LPV/r therapeutic drug monitoring (TDM) was determined at 12-hours. RESULTS: LPV/r TDM (ng/ml) did not show significant differences among CYP3A4 or CYP3A5 SNPs, although a mean lower level of LPV/r was associated with detection of several SNPs: CYP3A5*3 rs776746; CYP3A5 rs28365088, CYP3A5 rs15524, CYP3A4 rs2687116, and a not already described polymorphism CYP3A4 nt20338. In follow-up analysis, <90% adherence was the main factor associated with virological failure of LPV/r monotherapy (83.3% of failure vs 34.4%, p<0.001 at log-rank test). Adjusting for adherence, the detection of a single CYP3A5*3 rs776746 and CYP3A5 rs15524 SNPs was associated with higher probability of LPV/r monotherapy failure (p<0.01), and in general, detection of any CYP3A5 SNP was associated with failure (26.2% vs 58.3%, p=0.067). No-association with detection of any CYP3A4 SNPs was found. MDR1 TT variants showed significant lower frequency of treatment failure (0.0% vs 47.7%, p=0.026), since non-TT homozygote patient failed LPV/r monotherapy. CONCLUSIONS: Efficacy of PI monotherapy is strongly dependent from patient adherence, but, in adherent patients, genetic factors, such as CYP3A5 and MDR1-C3435T gene variants, may affect the response to treatment, though their role, as well of other genetic variants, need further investigation.","fulltextAvailable":false,"journal":"Journal of the International AIDS Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, MDR","uri":{"id":"D019450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Genetic","uri":{"id":"D011110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viral Load","uri":{"id":"D019562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Base Sequence","uri":{"id":"D001483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carrier Proteins","uri":{"id":"D002352","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Compliance","uri":{"id":"D010349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Failure","uri":{"id":"D017211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance, Multiple","uri":{"id":"D018432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nucleotides","uri":{"id":"D009711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV-1","uri":{"id":"D015497","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ritonavir","uri":{"id":"D019438","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biotransformation","uri":{"id":"D001711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterozygote","uri":{"id":"D006579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homozygote","uri":{"id":"D006720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"P-Glycoprotein","uri":{"id":"D020168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lopinavir","uri":{"id":"D061466","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25394094","title":"Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"This presentation focuses on the challenges and practical issues faced each day by orphans of the HIV epidemic and the holistic care that can be provided, as they continue to grow from toddlerhood to adolescence and beyond. An HIV Research Trust Scholarship enabled me to spend quality time in a sub-Saharan African province worst hit by the HIV epidemic and to interact with local experts and learn from mutual clinical experience. It was an immensely useful exercise as the clinical spectra of the diseases are very similar to ours and they have ongoing active research programs very relevant to our setting. India is arguably home to the largest number of orphans of the HIV epidemic. The responsibility of caring for orphaned children overwhelms and pushes many extended families beyond their ability to cope. Many countries are experiencing large increases in the number of families headed by women and grandparents, or even young children. These households are often unable to meet basic needs, and so the number of children living on the streets is rising. Orphaned children are disadvantaged in many devastating ways. In addition to the trauma of witnessing the sickness and death of one or both parents and perhaps siblings, they lack the necessary parental guidance through crucial life-stages of identity formation and transition into adulthood. They are more likely to suffer damage to their cognitive and emotional development and be subjected to; exploitation in terms of labour, social exclusion, extreme economic uncertainty, physical and sexual abuse, illiteracy, malnutrition and illness. Education remains a distant dream. With stigma and discrimination, they lack legal protection, lose inheritance rights, access to essential services available to other community members and professional help from doctors, teachers and lawyers. The implications for these unfortunate children are extraordinarily grave but governments, international agencies, non-governmental organizations, schools, other community groups and individuals can still alter the course of the crisis. The Committed Communities Development Trust (CCDT) is a voluntary secular Trust, reaching out to 300,000 people annually, focusing intensively on children affected and infected by HIV/AIDS, mainly orphans, child headed families, children living in street situations, brothels, institutions and children at risk of drug addiction, abuse and exploitation in Mumbai. We run several comprehensive HIV/AIDS programmes addressing issues of prevention, care, support, education, awareness, empowerment, training and research through strongly structured home-based care programs, community based programs and temporary residential shelters. The CCDT recognizes and understands the daunting challenges these children face and helps them overcome these as a team by providing comprehensive care and support, giving them an opportunity in life and enabling them to become productive citizens of tomorrow.","fulltextAvailable":false,"journal":"Journal of the International AIDS Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Government Agencies","uri":{"id":"D006077","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Users","uri":{"id":"D055030","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sex Offenses","uri":{"id":"D012742","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Substance-Related Disorders","uri":{"id":"D019966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Family","uri":{"id":"D005190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Agencies","uri":{"id":"D007390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organizations","uri":{"id":"D009938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research","uri":{"id":"D012106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Street Drugs","uri":{"id":"D013287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Orphaned","uri":{"id":"D054540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Family Characteristics","uri":{"id":"D005191","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Government","uri":{"id":"D006076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parents","uri":{"id":"D010290","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Power (Psychology)","uri":{"id":"D011209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Residence Characteristics","uri":{"id":"D012111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schools","uri":{"id":"D012574","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Socialism","uri":{"id":"D012950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Socialization","uri":{"id":"D012951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Symbiosis","uri":{"id":"D013559","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wills","uri":{"id":"D014918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Living Wills","uri":{"id":"D016224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sexuality","uri":{"id":"D019529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uncertainty","uri":{"id":"D035501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trust","uri":{"id":"D035502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secularism","uri":{"id":"D035621","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Siblings","uri":{"id":"D035781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malnutrition","uri":{"id":"D044342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemics","uri":{"id":"D058872","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tobacco Use Cessation Products","uri":{"id":"D061485","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acquired Immunodeficiency Syndrome","uri":{"id":"D000163","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Educational Status","uri":{"id":"D004522","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Empathy","uri":{"id":"D004645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"India","uri":{"id":"D007194","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wit and Humor as Topic","uri":{"id":"D014925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lawyers","uri":{"id":"D033241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Orphaned","uri":{"id":"D054540","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25393992","title":"Orphans of the HIV epidemic: the challenges from toddlerhood to adolescence and beyond.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The high mutation rate of the human immunodeficiency virus type 1 (HIV-1) virus is a major problem since it evades the function of antibodies and chemical inhibitors. Here, we demonstrate a viral detection strategy based on synthetic biology principles to detect a specific viral function rather than a particular viral protein. The resistance caused by mutations can be circumvented since the mutations that cause the loss of function also incapacitate the virus. Many pathogens encode proteases that are essential for their replication and that have a defined substrate specificity. A genetically encoded sensor composed of a fused membrane anchor, viral protease target site, and an orthogonal transcriptional activator was engineered into a human cell line. The HIV-1 protease released the transcriptional activator from the membrane, thereby inducing transcription of the selected genes. The device was still strongly activated by clinically relevant protease mutants that are resistant to protease inhibitors. In the future, a similar principle could be applied to detect also other pathogens and functions.","fulltextAvailable":false,"journal":"ACS synthetic biology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ambulatory Care Facilities","uri":{"id":"D000554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV-1","uri":{"id":"D015497","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protease Inhibitors","uri":{"id":"D011480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptional Activation","uri":{"id":"D015533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Substrate Specificity","uri":{"id":"D013379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viral Proteins","uri":{"id":"D014764","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synthetic Biology","uri":{"id":"D058615","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation Rate","uri":{"id":"D059645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Equipment and Supplies","uri":{"id":"D004864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Hydrolases","uri":{"id":"D010447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV-1","uri":{"id":"D015497","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Principle-Based Ethics","uri":{"id":"D028662","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteolysis","uri":{"id":"D059748","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25393958","title":"Function-based mutation-resistant synthetic signaling device activated by HIV-1 proteolysis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AIMS: Previously published pharmacokinetics (PK) models for sunitinib and its active metabolite SU12662 were based on a limited dataset or lacked important elements such us correlations between sunitinib and its metabolite. The current study was to develop an improved PK model that circumvented these limitations and to prove the utility of the PK model in treatment optimisation in clinical practice. METHODS: 1205 plasma samples from 70 cancer patients were collected from three PK studies with sunitinib and SU12662. A semi-physiological PK model for sunitinib and SU12662 was developed incorporating pre-systemic metabolism using nonlinear mixed-effects modelling (NONMEM). Allometric scaling based on body weight was applied. The final model was used for simulation of the PK of different treatment regimens. RESULTS: Sunitinib and SU12662 PK were best described by one and two compartment model, respectively. Introduction of pre-systemic formation of SU12662 strongly improved model fit, compared to solely systemic metabolism. The clearance of sunitinib and SU12662 was estimated at 35.7 (relative standard error (RSE) 5.7%) L·h(-1) and 17.1 (RSE 7.4%) L·h(-1) , respectively for 70 kg patients. Correlation coefficients were estimated between inter-individual variability of both clearances, both volume of distributions, and between clearance and volume of distribution of SU12662 as 0.53, 0.48 and 0.45, respectively. Simulation of the PK model predicted correctly the ratio of patients that not reaching proposed PK targets for efficacy. CONCLUSIONS: A semi-physiological PK model for sunitinib and SU12662 in cancer patients was presented including pre-systemic metabolism. The model was superior to previous PK models in multiple aspects.","fulltextAvailable":false,"journal":"British journal of clinical pharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nonlinear Dynamics","uri":{"id":"D017711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Body Weight","uri":{"id":"D001835","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25393890","title":"Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: N-type voltage-dependent Ca(2+) channels (CaV 2.2) are located at nerve endings in the central and peripheral nervous systems and are strongly associated with the pathological processes of cerebral ischemia and neuropathic pain. CaV 2.2 blockers such as the ω-conotoxin MVIIA (Prialt) are analgesic and have opioid-sparing effects. With the aim to develop new multi-target analgesic compounds, we designed the first ω-conotoxin/opioid peptidomimetics based on the enkephalin-like sequence Tyr-D-Ala-Gly-Phe (for the opioid portion) and two fragments derived from the loop-2 pharmacophore of ω-conotoxin MVIIA. Antinociceptive activity evaluated in vitro and in vivo revealed differential affinity for CaV 2.2 and opioid receptors and no significant synergistic activity. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"Chemical biology & drug design","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Ischemia","uri":{"id":"D002545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Endings","uri":{"id":"D009411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuralgia","uri":{"id":"D009437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathologic Processes","uri":{"id":"D010335","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Opioid","uri":{"id":"D011957","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Nervous System","uri":{"id":"D017933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics, Opioid","uri":{"id":"D000701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemia","uri":{"id":"D007511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptidomimetics","uri":{"id":"D057786","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25393330","title":"Design, Synthesis and Biological evaluation of two opioid agonist and Cav 2.2 blocker multi-target ligands.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Both gram-positive and gram-negative pathogens or pathogen-derived components, such as staphylococcal enterotoxins (SEs) and endotoxin (LPS) exposure, activate MyD88-mediated pro-inflammatory cellular immunity for host defense. However, dys-regulated MyD88-mediated signaling triggers exaggerated immune response that often leads to toxic shock and death. Previously, we reported a small molecule compound 1 mimicking BB-loop structure of MyD88 was capable of inhibiting pro-inflammatory response to SEB exposure in mice. In this study, we designed a dimeric structure compound 4210 covalently linked with compound 1 by a non-polar cyclohexane linker which strongly inhibited the production of pro-inflammatory cytokines in human primary cells to SEB (IC50 1-50 μM) or LPS extracted from Francisella tularensis, Escherichia coli, or Burkholderia mallei (IC50 10-200 μM). Consistent with cytokine inhibition, in a ligand-induced cell-based reporter assay, compound 4210 inhibited B. mallei or LPS-induced MyD88-mediated NF-kB-dependent expression of reporter activity (IC50 10-30 μM). Furthermore, results from a newly expressed MyD88 revealed that 4210 inhibited MyD88 dimer formation which is critical for pro-inflammatory signaling. Importantly, a single administration of compound 4210 in mice showed complete protection from lethal toxin challenge. Collectively, these results demonstrated that compound 4210 inhibits toxin-induced inflated pro-inflammatory immune signaling, thus displays a potential bacterial toxin therapeutic. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"Chemical biology & drug design","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia coli","uri":{"id":"D004926","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bacterial Toxins","uri":{"id":"D001427","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Cellular","uri":{"id":"D007111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Shock, Septic","uri":{"id":"D012772","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Burkholderia mallei","uri":{"id":"D042726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endotoxins","uri":{"id":"D004731","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Escherichia","uri":{"id":"D004925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exhibits as Topic","uri":{"id":"D005085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Burkholderia","uri":{"id":"D019117","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dimerization","uri":{"id":"D019281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclohexanes","uri":{"id":"D003510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enterotoxins","uri":{"id":"D004768","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Francisella","uri":{"id":"D005603","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Francisella tularensis","uri":{"id":"D005604","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inhibitory Concentration 50","uri":{"id":"D020128","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25393063","title":"Structure-Based Design and Synthesis of a Small Molecule that Exhibits Anti-inflammatory Activity by Inhibition of MyD88-mediated Signaling to Bacterial Toxin Exposure.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVES: Cerebellar ataxia can be induced by a large number of drugs. We here conducted a systemic review of the drugs that can lead to cerebellar ataxia as an adverse drug reaction (ADR). METHODS: We performed a systematic literature search in Pubmed (1966 to January 2014) and EMBASE (1988 to January 2014) to identify all of the drugs that can have ataxia as an ADR and to assess the frequency of drug-induced ataxia for individual drugs. Furthermore, we collected reports of drug-induced ataxia over the past 20 years in the Netherlands by querying a national register of ADRs. RESULTS: Drug-induced ataxia was reported in association with 93 individual drugs (57 from the literature, 36 from the Dutch registry). The most common groups were antiepileptic drugs, benzodiazepines, and antineoplastics. For some, the number needed to harm was below 10. Ataxia was commonly reversible, but persistent symptoms were described with lithium and certain antineoplastics. CONCLUSIONS: It is important to be aware of the possibility that ataxia might be drug-induced, and for some drugs the relative frequency of this particular ADR is high. In most patients, symptoms occur within days or weeks after the introduction of a new drug or an increase in dose. In general, ataxia tends to disappear after discontinuation of the drug, but chronic ataxia has been described for some drugs.","fulltextAvailable":false,"journal":"CNS drugs","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebellar Ataxia","uri":{"id":"D002524","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lithium","uri":{"id":"D008094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Netherlands","uri":{"id":"D009426","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Registries","uri":{"id":"D012042","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ataxia","uri":{"id":"D001259","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzodiazepines","uri":{"id":"D001569","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25391707","title":"Drug-induced cerebellar ataxia: a systematic review.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: -Ictal asystole is a rare, serious, and often treatable cause of syncope. There are currently limited data to guide management. Characterization of ictal syncope predictors may aid in the selection of high-risk patients for treatments such as pacemakers. METHODS AND RESULTS: -We searched our epilepsy monitoring unit database from October 2003 through July 2013 for all patients with ictal asystole events. Clinical, EEG, and ECG data for each of their seizures were examined for their relationships with ictal syncope events. In 10 patients with ictal asystole, we observed 76 clinical seizures with 26 ictal asystole episodes, 15 of which led to syncope. No seizure with asystole duration ≤6 seconds led to syncope, while 94% (15/16) of seizures with asystole duration >6 seconds led to syncope (P=0.02). During ictal asystole events, 4 patients had left temporal seizure onset, 4 patients had right temporal seizure onset, and 2 patients had both. Syncope was more common with left temporal (40%) than right temporal seizures (10%; P=0.002). Treatment options included anti-epileptic drug changes, epilepsy surgery, and/or pacemaker implantation. Eight patients received pacemakers. During follow-up of 72±95 months, all patients remained syncope-free. CONCLUSIONS: -Ictal asystole >6 seconds is strongly associated with ictal syncope. Ictal syncope is more common in left than right temporal seizures. A permanent pacemaker should be considered in patients with ictal syncope if they are not considered good candidates for epilepsy surgery.","fulltextAvailable":false,"journal":"Circulation. Arrhythmia and electrophysiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Rights","uri":{"id":"D028701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrocardiography","uri":{"id":"D004562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroencephalography","uri":{"id":"D004569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Arrest","uri":{"id":"D006323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syncope","uri":{"id":"D013575","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25391254","title":"Ictal Asystole and Ictal Syncope: Insights into Clinical Management.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Introduction: The majority of therapeutics, small molecule or biologics, developed for the CNS do not penetrate the blood-brain barrier (BBB) sufficiently to induce pharmacologically meaningful effects on CNS targets. To improve the efficiency of CNS drug discovery, several in vitro models of the BBB have been used to aid early selection of molecules with CNS exposure potential. However, correlative studies suggest relatively poor predictability of in vitro BBB models underscoring the need to combine in vitro and in vivo BBB penetration assessment into an integrated preclinical workflow. Areas covered: This review gives a brief general overview of in vitro and in vivo BBB models used in the pre-clinical evaluation of CNS-targeting drugs, with particular focus on the recent progress in developing humanized models. The authors discuss the advantages, limitations, in vitro-in vivo correlation, and integration of these models into CNS drug discovery and development with the aim of improving translation. Expert opinion: Often, a simplistic rationalization of the CNS drug discovery and development process overlooks or even ignores the need for an early and predictive assessment of the BBB permeability. Indeed, past failures of CNS candidates in clinical trials argue strongly that the early deployment of in vitro and in vivo models for assessing BBB permeability, mechanisms of transport and brain exposure of leads, and the co-development of BBB delivery strategies will improve translation and increase the clinical success of CNS pipelines.","fulltextAvailable":false,"journal":"Expert opinion on drug discovery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Expert Testimony","uri":{"id":"D005104","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Human Development","uri":{"id":"D006803","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Workflow","uri":{"id":"D057188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Permeability","uri":{"id":"D010539","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rationalization","uri":{"id":"D011908","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25388782","title":"Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Evidence for the involvement of the Substance P (SP)/NK1 receptor system in the development and progression of cancer strongly supports its potential as a therapeutic target in malignancies. Novel strategies for approaching cancer treatment are urgently required particularly with regard to tumours of the central nervous system (CNS), which are notoriously difficult to effectively treat and associated with extremely poor prognosis for many patients. This is due, in part, to the presence of the highly specialised blood-brain barrier, which is known to restrict common treatments such as chemotherapy and hinder early tumour diagnosis. Additionally, tumours of the CNS are difficult to surgically resect completely, often contributing to the resurgence of the disease many years later. Interestingly, despite the presence of the blood-brain barrier, circulating tumour cells are able to gain entry to the brain and form secondary brain tumours; however, the underlying mechanisms of this process remain unclear. Tachykinins, in particular Substance P, have been implicated in early blood-brain barrier disruption via neurogenic inflammation in a number of other CNS pathologies. Recent evidence also suggests that Substance P may play a central role in the development of CNS tumours. It has been well established that a number of tumour cells express Substance P, NK1 receptors and mRNA for the tachykinin NK1 receptor. This increase in the Substance P/NK1 receptor system is known to induce proliferation and migration of tumour cells as well as stimulate angiogenesis, thus contributing to tumour progression. Accordingly, the NK1 receptor antagonist presents a novel target for anti-cancer therapy for which a number of patents have been filed. This review will examine the role of Substance P in the development of CNS tumours and its potential application as an anti-cancer agent.","fulltextAvailable":false,"journal":"Recent patents on CNS drug discovery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Neurokinin-1","uri":{"id":"D018040","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Tachykinin","uri":{"id":"D018039","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Diagnosis","uri":{"id":"D042241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiogenesis Inducing Agents","uri":{"id":"D043925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Substance P","uri":{"id":"D013373","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurogenic Inflammation","uri":{"id":"D020078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Filing","uri":{"id":"D005371","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tachykinins","uri":{"id":"D015320","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25386916","title":"Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-Inflammatory Peptide Substance P and its Antagonists as Anti-Cancer Agents.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Schistosomiasis is a major health problem in tropical and sub-tropical areas caused by species of trematode belonging to the genus Schistosoma. The treatment and control of this disease has been relying on the use of a single drug praziquantel. However, the drug resistance concern urged the development of new drugs against schistosoma. Here, we report our systematic biological evaluation of DW-3-15, a new lead compound developed based on our conjugation design rationale as an effective anti-schistosomal agent. METHODOLOGY/PRINCIPAL FINDINGS: The antischistosomal activity of DW-3-15 was systematically evaluated in S. japonicum infected mouse model for its stage-sensitivity and dose response. The results revealed that DW-3-15 exhibited 60-85% worm reduction rate against different development stage of worm. Scanning electron microscopy (SEM) observation indicated that DW-3-15 may damage to the tegument of male schistosomes. CONCLUSIONS/SIGNIFICANCE: Our results demonstrated that DW-3-15 showed potent anti-schistosomal activities in vivo. The results strongly support our conjugation design strategy of artemisinin analogs and further development of DW-3-15 as a new lead compound as anti-schistosomal agent.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schistosomicides","uri":{"id":"D012556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Praziquantel","uri":{"id":"D011223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schistosoma","uri":{"id":"D012547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schistosomiasis","uri":{"id":"D012552","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Artemisinins","uri":{"id":"D037621","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25386745","title":"An artemisinin derivative of praziquantel as an orally active antischistosomal agent.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AP736 was identified as an antimelanogenic drug that can be used for the prevention of melasma, freckles, and dark spots in skin by acting as a suppressor of melanin synthesis and tyrosinase expression. Since macrophage-mediated inflammatory responses are critical for skin health, here we investigated the potential anti-inflammatory activity of AP736. The effects of AP736 on various inflammatory events such as nitric oxide (NO)/prostaglandin (PG) E2 production, inflammatory gene expression, phagocytic uptake, and morphological changes were examined in RAW264.7 cells. AP736 was found to strongly inhibit the production of both NO and PGE2 in lipopolysaccharide- (LPS-) treated RAW264.7 cells. In addition, AP736 strongly inhibited both LPS-induced morphological changes and FITC-dextran-induced phagocytic uptake. Furthermore, AP736 also downregulated the expression of multiple inflammatory genes, such as inducible NO synthase (iNOS), cyclooxygenase- (COX-) 2, and interleukin- (IL-) 1β in LPS-treated RAW264.7 cells. Transcription factor analysis, including upstream signalling events, revealed that both NF-κB and AP-1 were targeted by AP736 via inhibition of the IKK/IκBα and IRAK1/TAK1 pathways. Therefore, our results strongly suggest that AP736 is a potential anti-inflammatory drug due to its suppression of NF-κB-IKK/IκBα and AP-1-IRAK1/TAK1 signalling, which may make AP736 useful for the treatment of macrophage-mediated skin inflammation.","fulltextAvailable":false,"journal":"Mediators of inflammation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Synergism","uri":{"id":"D004357","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dinoprostone","uri":{"id":"D015232","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclooxygenase 2","uri":{"id":"D051546","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Analysis, Statistical","uri":{"id":"D005163","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nitric Oxide","uri":{"id":"D009569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nitric Oxide Synthase","uri":{"id":"D019001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukins","uri":{"id":"D007378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipopolysaccharides","uri":{"id":"D008070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanins","uri":{"id":"D008543","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanosis","uri":{"id":"D008548","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phagocytes","uri":{"id":"D010586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandin-Endoperoxide Synthases","uri":{"id":"D011451","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandins","uri":{"id":"D011453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monophenol Monooxygenase","uri":{"id":"D014442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dinoprostone","uri":{"id":"D015232","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factor AP-1","uri":{"id":"D018808","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25386046","title":"NF-κB/AP-1-Targeted Inhibition of Macrophage-Mediated Inflammatory Responses by Depigmenting Compound AP736 Derived from Natural 1,3-Diphenylpropane Skeleton.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AIM: Patient's perception of seizure precipitant is crucial in epilepsy management, but it is often overlooked by physicians. This may be due to neglect and underestimation of its importance. This study looked at frequency and nature of self-perceived seizure precipitants among patients with epilepsy. MATERIALS AND METHODS: A close-ended questionnaire-based study. Patients with active epilepsy (≥2 attacks/year) were recruited from the neurology clinic of the University of Ilorin Teaching Hospital (UITH), Ilorin. RESULT: A total of 89 patients participated in the study and of these 41 (46.1%) were males. Their median age was 30 (21-52) years and median age at seizure onset was 22 (15-46) years. The median seizure duration was five (2-14) years. More patients (46.1%) had less than secondary school education and 12 (13.5) were uneducated. Generalized epilepsy was the predominant (68.6%) seizure type. A total of 33 (37.1%) subjects had ≥4 attacks/year, 29 (32.6%) had 5-12 attacks/year, and 27 (30.3%) >12 attacks/year. A total of 16 (18%) subjects did not mention any seizure precipitant, whereas 73 (82.2%) reported at least one specific seizure precipitant; of these, 62 (85%) patients reported ≥2 precipitants. Stress (41%), inadequate sleep (27%), and head trauma (26%) were the three leading seizure precipitants mentioned. Subject's age, sex, level of seizure control, and place of abode did not influence reported seizure precipitants. However, the more educated (>12 years education) patients significantly reported stress as seizure precipitant (P < 0.05). Most (80%) patients rightly indicated that antiepileptic drug was the best treatment for their seizure control. CONCLUSION: The result of this study showed that the leading perceived seizure precipitants among epilepsy patients attending the neurology clinic of UITH were stress, inadequate sleep, head trauma, and demonic attacks and spells.","fulltextAvailable":false,"journal":"Nigerian journal of clinical practice","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age of Onset","uri":{"id":"D017668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schools","uri":{"id":"D012574","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy, Generalized","uri":{"id":"D004829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Craniocerebral Trauma","uri":{"id":"D006259","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Teaching","uri":{"id":"D006784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Participation","uri":{"id":"D010358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perception","uri":{"id":"D010465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schools","uri":{"id":"D012574","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurology","uri":{"id":"D009462","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nigeria","uri":{"id":"D009549","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Teaching","uri":{"id":"D013663","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25385905","title":"Self-perceived seizure precipitants among patients with epilepsy in Middle-belt of Nigeria.","year":"2014 Nov-Dec"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVES: Sudden unexplained/unexpected death (SUDEP) is related to high mortality in patients with epilepsy. The prolongation of QT interval, involved in cardiac arrhythmia-related SUDEP, may be precipitated by antiepileptic dru gs (AEDs). In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures. METHODS: We performed an open-label, parallel group, prospective, multicenter study between June 2009 and December 2013 in patients older than 18 years of age with a clinical diagnosis of post-stroke seizure and treated with phenobarbital or levetiracetam. In order to exclude a role of cerebral post-stroke injury on modulation of PR and QTc intervals, patients with cerebral post-stroke injury and without seizures were also enrolled as controls. RESULTS: Interictal electrocardiography analysis revealed no significant difference in PR interval between patients treated with an AED (n = 49) and control patients (n = 50) (181.25 ± 12.05 vs. 182.4 ± 10.3 ms; p > 0.05). In contrast, a significantly longer QTc interval was recorded in patients treated with an AED compared with control patients (441.2 ± 56.6 vs. 396.8 ± 49.3 ms; p < 0.01). Patients treated with phenobarbital showed a significantly longer QTc interval than patients treated with levetiracetam (460.0 ± 57.2 vs. 421.5 ± 50.1 ms; p < 0.05). CONCLUSIONS: The study reported that in patients with late post-stroke seizures, phenobarbital prolonged QTc interval more so than levetiracetam.","fulltextAvailable":false,"journal":"Clinical drug investigation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrocardiography","uri":{"id":"D004562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenobarbital","uri":{"id":"D010634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25385363","title":"Effects of Phenobarbital and Levetiracetam on PR and QTc Intervals in Patients with Post-Stroke Seizure.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Abstract Neonatal crises are a common problem in the first month, where phenobarbital and phenytoin are still the most frequently used medication in treatment. Whereas, Levetiracetam (LEV) is an antiepileptic drug (AED) with an innovative action. Our present review is updated on the current literature regarding use of LEV in neonatal seizures treatment. The available data is analyzed to assess LEV pharmacokinetics, efficacy and tolerability in neonatal crises treatment. Several clinical trials, prospective and retrospective, comparative and pharmacokinetic studies were evaluated in LEV pharmacokinetics, efficacy, dosage, route of administration and side effects. Many cases were reported on neonatal seizures control in using LEV in certain clinical conditions. In spite of the limitations in current studies available which have evaluated LEV efficacy and safety in neonatal crises treatment, the authors still believe that LEV seems to be a promising and useful AED in the treatment for neonatal seizures, but likewise further studies are required to better define LEV efficacy and tolerability in term and preterm neonates.","fulltextAvailable":false,"journal":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant, Newborn","uri":{"id":"D007231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenobarbital","uri":{"id":"D010634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25385270","title":"The treatment of neonatal seizures: focus on Levetiracetam.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The pathogenic yeast Candida albicans can develop resistance to azole antifungal drugs by overexpressing ERG11, which encodes the drug target, or the multidrug efflux pumps MDR1 and CDR1/CDR2. The constitutive upregulation of these genes is usually caused by gain-of-function mutations in the zinc cluster transcription factors Upc2, Mrr1, and Tac1, respectively. These transcription factors are also required for the induction of their target genes in drug-susceptible strains in the presence of specific stimuli. By swapping the DNA-binding domains of Mrr1, Tac1, and Upc2 we investigated if the hybrid transcription factors could activate their new target genes in response to the same signals. When Tac1 was targeted to the MDR1 and ERG11 promoters, the expression of these genes became inducible by fluphenazine. Similarly, MDR1 and CDR2 were strongly upregulated by fluconazole when Upc2 was fused to the DNA-binding domains of Mrr1 and Tac1, respectively. In contrast, Mrr1 was unable to promote gene expression in response to benomyl when it was targeted to the CDR2 and ERG11 promoters instead of the MDR1 promoter. These results suggest that Tac1 and Upc2 themselves are activated by the inducers fluphenazine and fluconazole, respectively, whereas benomyl does not activate Mrr1 itself but a coregulatory factor that is present at the promoters of Mrr1 target genes. Strains in which the expression of Mrr1 and Tac1 target genes was controlled by Upc2 exhibited increased fluconazole resistance, demonstrating that the ability to efficiently upregulate the expression of efflux pumps in the presence of the drug results in enhanced intrinsic fluconazole resistance.","fulltextAvailable":false,"journal":"Antimicrobial agents and chemotherapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Targeting","uri":{"id":"D018390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Candida albicans","uri":{"id":"D002176","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Candida","uri":{"id":"D002175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Zinc","uri":{"id":"D015032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cluster Analysis","uri":{"id":"D016000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Azoles","uri":{"id":"D001393","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benomyl","uri":{"id":"D001542","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Danazol","uri":{"id":"D003613","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluphenazine","uri":{"id":"D005476","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Yeasts","uri":{"id":"D015003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluconazole","uri":{"id":"D015725","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25385116","title":"Induction of Candida albicans drug resistance genes by hybrid zinc cluster transcription factors.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: An increase in the H2S (hydrogen sulfide, hereafter sulfide) concentration in pulmonary artery smooth muscle cells (PASMCs) has been proposed to mediate hypoxic pulmonary vasoconstriction (HPV). We evaluated this hypothesis in isolated rat intrapulmonary arteries (IPA) by examining the effects of the sulfide precursor cysteine and sulfide-synthesis blockers on HPV and also on normoxic pulmonary vasoconstriction (NPV) stimulated by PGF2α and by the drug LY83583, which causes contraction in IPA by increasing cellular ROS levels. Experiments with several blockers of cystathionine γ lyase (CSE), the enzyme responsible for sulfide synthesis in the vasculature, demonstrated that propargylglycine (PAG; 1 mM) had little or no effect on the NPV caused by PGF2α or LY83583. Conversely, other CSE antagonists tested aminooxyacetic acid (AOAA, 100 μM), β-cyanoalanine (BCA, 500 μM) and hydroxylamine (HA, 100μM) altered the NPV to PGF2α (BCA increased, HA inhibited) and/or LY83583 (BCA increased, AOAA and HA inhibited). Preincubating IPA in PSS containing 1 mM cysteine increased the amplitude of the NPV to PGF2α by ∼50%, and had a similar effect on HPV elicited by hypoxic challenge with 0% O2. The enhancement of both responses by cysteine was abolished by pretreatment with 1 mM PAG. Measurements carried out with an amperometric electrode demonstrated that incubation with 1 mM cysteine under anoxic conditions (to minimize sulfide oxidation) greatly potentiated the release of sulfide from pieces of rat liver and that this release was strongly antagonized by PAG, indicating that at this concentration PAG could enter cells intact and antagonise CSE. 1 mM PAG had no effect on HPV recorded in control PSS, or in PSS supplemented with physiological concentrations of cysteine (10 μM), cystine (50 μM) and glutamate (100 μM) in order to prevent the possible depletion of intracellular cysteine during experiments. Application of a combination of 1 mM cysteine and 1 mM α ketoglutarate to promote sulfide synthesis via the cysteine aminotransferase/ mercaptopyruvate sulfurtransferase (CAT/MST) pathway caused an increase in HPV similar to that observed for cysteine. This was partially blocked by the CAT antagonist aspartate (1 mM) and also by PAG. However, HPV was not increased by 1 mM α ketoglutarate alone, and HPV in the absence of α ketoglutarate and cysteine was not attenuated by aspartate. Pretreatment of IPA with dithiothreitol (DTT, 1 mM), proposed to promote the conversion of mitochondrial thiosulfate to sulfide, did not increase the release of sulfide from pieces of rat liver in either the presence or absence of 1 mM cysteine, and virtually abolished HPV. The results provide evidence that the sulfide precursor cysteine can promote both NPV and HPV in rat IPA by generating sulfide via a PAG-sensitive pathway, presumably CSE. However, HPV evoked under control conditions was unaffected by the blockade of CSE. Moreover, HPV was not affected by the CAT antagonist asparate and was blocked rather than enhanced by DTT. The data therefore indicate that sulfide generated by CSE or CAT/MST or from thiosulfate is unlikely to contribute to O2 sensing during HPV in these arteries. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"The Journal of physiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forms and Records Control","uri":{"id":"D005568","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aminooxyacetic Acid","uri":{"id":"D000625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen Sulfide","uri":{"id":"D006862","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle, Smooth","uri":{"id":"D009130","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulmonary Artery","uri":{"id":"D011651","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle Cells","uri":{"id":"D032342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocytes, Smooth Muscle","uri":{"id":"D032389","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cysteine","uri":{"id":"D003545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrodes","uri":{"id":"D004566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glutamates","uri":{"id":"D005971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen","uri":{"id":"D006859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogenation","uri":{"id":"D006865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incubators","uri":{"id":"D007185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscles","uri":{"id":"D009132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glutamic Acid","uri":{"id":"D018698","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aminooxyacetic Acid","uri":{"id":"D000625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transaminases","uri":{"id":"D000637","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspartic Acid","uri":{"id":"D001224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cystathionine","uri":{"id":"D003540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cystine","uri":{"id":"D003553","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dithiothreitol","uri":{"id":"D004229","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxylamines","uri":{"id":"D006898","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lyases","uri":{"id":"D008190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfides","uri":{"id":"D013440","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfurtransferases","uri":{"id":"D013466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thiosulfates","uri":{"id":"D013885","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasoconstriction","uri":{"id":"D014661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxylamine","uri":{"id":"D019811","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25384779","title":"Hypoxic pulmonary vasoconstriction in isolated rat pulmonary arteries is not inhibited by antagonists of H2S-synthesizing pathways.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The purpose of this study was to assess the classes and types of psychotropic medication reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. Medication use was assessed at baseline using a semistructured interview of proven reliability and validity as well as its follow-up analog at 8 contiguous 2-year follow-up periods. A significantly higher percentage of borderline patients than axis II comparison subjects reported taking an antidepressant, an anxiolytic, an antipsychotic, and a mood stabilizer over time. They also reported more commonly taking 7 of the 10 more specific types of medication studied (ie, all but tricyclic antidepressants, monoamine oxidase inhibitor antidepressants, and atypical antipsychotics). The rates over time of taking antipsychotics and mood stabilizers were stable, whereas there was a significant decline in the rates of antidepressants and anxiolytics from baseline to 8-year follow-up (but not from 8- to 16-year follow-up) reported by those in both study groups. In terms of specific medications, rates of atypical antidepressants and anticonvulsants were the most stable. In contrast, nonbenzodiazepine anxiolytics declined the most steadily over time, whereas rates of atypical antipsychotics increased significantly over the 16 years of prospective follow-up. Taken together, the results of this study suggest that a substantial percentage of borderline patients continue to use the major classes of medication over time. They also suggest that the declining rates of use tend to stabilize less than a decade after index admission.","fulltextAvailable":false,"journal":"Journal of clinical psychopharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents, Second-Generation","uri":{"id":"D018687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reproducibility of Results","uri":{"id":"D015203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents, Tricyclic","uri":{"id":"D000929","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monoamine Oxidase","uri":{"id":"D008995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monoamine Oxidase Inhibitors","uri":{"id":"D008996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents, Second-Generation","uri":{"id":"D018687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Axis","uri":{"id":"D001368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidoreductases","uri":{"id":"D010088","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents","uri":{"id":"D000928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Anxiety Agents","uri":{"id":"D014151","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25384261","title":"Rates of Psychotropic Medication Use Reported by Borderline Patients and Axis II Comparison Subjects Over 16 Years of Prospective Follow-Up.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"TNF-α plays a crucial role in psoriasis; therefore, TNF inhibition has become a gold standard for the treatment of psoriasis. TNF-α is processed from a membrane-bound form by TNF-α converting enzyme (TACE) to soluble form, which exerts a number of biological activities. EGF receptor (EGFR) ligands, including heparin-binding EGF-like growth factor (HB-EGF), amphiregulin and transforming growth factor (TGF)-α are also TACE substrates and are psoriasis-associated growth factors. Vascular endothelial growth factor (VEGF), one of the downstream molecules of EGFR and TNF signaling, plays a key role in angiogenesis for developing psoriasis. In the present study, to assess the possible role of TACE in the pathogenesis of psoriasis, we investigated the involvement of TACE in TPA-induced psoriasis-like lesions in K5.Stat3C mice, which represent a mouse model of psoriasis. In this mouse model, TNF-α, amphiregulin, HB-EGF and TGF-α were significantly up-regulated in the skin lesions, similar to human psoriasis. Treatment of K5.Stat3C mice with TNF-α or EGFR inhibitors attenuated the skin lesions, suggesting the roles of TACE substrates in psoriasis. Furthermore, the skin lesions of K5.Stat3C mice showed down-regulation of tissue inhibitor of metalloproteinase-3, an endogenous inhibitor of TACE, and an increase in soluble TNF-α. A TACE inhibitor abrogated EGFR ligand-dependent keratinocyte proliferation and VEGF production in vitro, suggesting that TACE was involved in both epidermal hyperplasia and angiogenesis during psoriasis development. These results strongly suggest that TACE contributes to the development of psoriatic lesions through releasing two kinds of psoriasis mediators, TNF-α and EGFR ligands. Therefore, TACE could be a potential therapeutic target for the treatment of psoriasis.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endothelial Growth Factors","uri":{"id":"D016228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Signaling Peptides and Proteins","uri":{"id":"D036341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor, Epidermal Growth Factor","uri":{"id":"D011958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transforming Growth Factors","uri":{"id":"D015291","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Inhibitor of Metalloproteinase-3","uri":{"id":"D019717","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hyperplasia","uri":{"id":"D006965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidermal Growth Factor","uri":{"id":"D004815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psoriasis","uri":{"id":"D011565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Keratinocytes","uri":{"id":"D015603","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25384035","title":"Involvement of TNF-α Converting Enzyme in the Development of Psoriasis-Like Lesions in a Mouse Model.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"In directed C-H activation reactions, any nitrogen or sulphur atoms present in heterocyclic substrates will coordinate strongly with metal catalysts. This coordination, which can lead to catalyst poisoning or C-H functionalization at an undesired position, limits the application of C-H activation reactions in heterocycle-based drug discovery, in which regard they have attracted much interest from pharmaceutical companies. Here we report a robust and synthetically useful method that overcomes the complications associated with performing C-H functionalization reactions on heterocycles. Our approach employs a simple N-methoxy amide group, which serves as both a directing group and an anionic ligand that promotes the in situ generation of the reactive PdX2 (X = ArCONOMe) species from a Pd(0) source using air as the sole oxidant. In this way, the PdX2 species is localized near the target C-H bond, avoiding interference from any nitrogen or sulphur atoms present in the heterocyclic substrates. This reaction overrides the conventional positional selectivity patterns observed with substrates containing strongly coordinating heteroatoms, including nitrogen, sulphur and phosphorus. Thus, this operationally simple aerobic reaction demonstrates that it is possible to bypass a fundamental limitation that has long plagued applications of directed C-H activation in medicinal chemistry.","fulltextAvailable":false,"journal":"Nature","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry, Pharmaceutical","uri":{"id":"D002626","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amides","uri":{"id":"D000577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amiloride","uri":{"id":"D000584","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anions","uri":{"id":"D000838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry","uri":{"id":"D002621","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorus","uri":{"id":"D010758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidants","uri":{"id":"D016877","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nitrogen","uri":{"id":"D009584","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plague","uri":{"id":"D010930","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25383516","title":"Overcoming the limitations of directed C-H functionalizations of heterocycles.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Objective. The study aimed to evaluate the influences of coadministration of antiepileptic drugs (AEDs) on an antimalarial candidate 99/411 pharmacokinetic (PK) profile. Method. For this, single oral dose PK drug interaction studies were conducted between 99/411 and FDA approved AEDs, namely, Phenytoin (PHT), Carbamazepine (CBZ), and Gabapentin (GB) in both male and female SD rats, to assess the coadministered and intersexual influences on 99/411 PK profile. Results. Studies revealed that there were no significant alterations in the PK profile of 99/411 upon PHT and CBZ coadministration in both male and female rats, while systemic exposure of 99/411 was significantly increased by about 80% in female rats upon GB coadministration. In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL. Overall, it was concluded that simultaneous administration of AEDs with 99/411 excludes the requirements for dose adjustment, additional therapeutic monitoring, contraindication to concomitant use, and/or other measures to mitigate risk, except for GB coadministration in females. These findings are further helpful to predict such interactions in humans, when potentially applied through proper allometric scaling to extrapolate the data.","fulltextAvailable":false,"journal":"Malaria research and treatment","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Names","uri":{"id":"D009275","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Area Under Curve","uri":{"id":"D019540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antimalarials","uri":{"id":"D000962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbamazepine","uri":{"id":"D002220","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disorders of Sex Development","uri":{"id":"D012734","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25383231","title":"Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Adenosine (Ado) and some non-adenosine (non-Ado) nucleosides including inosine (Ino), guanosine (Guo) and uridine (Urd) are modulatory molecules in the central nervous system (CNS), regulating different physiological and pathophysiological processes in the brain such as sleep and epilepsy. Indeed, different drugs effective on adenosinergic system (e.g., Ado metabolism inhibitors, agonists and antagonists of Ado receptors) are being used in drug development for the treatment of epileptic disorders. Although (i) endogenous Ino, Guo and Urd showed anticonvulsant/antiepileptic effects (e.g., in quinolinic acid - induced seizures and in different epilepsy models such as hippocampal kindling models), and (ii) there is need to generate new and more effective antiepileptic drugs for the treatment of drug-resistant epilepsies, our knowledge about antiepileptic influence of non-Ado nucleosides is far from complete. Thus, in this review article, we give a short summary of anticonvulsant/antiepileptic effects and mechanisms evoked by Ino, Guo, and Urd. Finally, we discuss some non-Ado nucleoside derivatives and their structures, which may be candidates as potential antiepileptic agents.","fulltextAvailable":false,"journal":"Mini reviews in medicinal chemistry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quinolinic Acids","uri":{"id":"D011805","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quinolinic Acid","uri":{"id":"D017378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenosine","uri":{"id":"D000241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nucleosides","uri":{"id":"D009705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Guanosine","uri":{"id":"D006151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inosine","uri":{"id":"D007288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quinolines","uri":{"id":"D011804","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uridine","uri":{"id":"D014529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quinolinic Acid","uri":{"id":"D017378","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25382017","title":"Non-adenosine Nucleoside Inosine, Guanosine and Uridine as Promising Antiepileptic Drugs: a Summary of Current Literature.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The purpose of this study was to evaluate intestinal absorption, organ distribution, and urinary elimination of the rare sugar D-psicose, a 3-carbon stereoisomer of D-fructose that is currently being investigated and which has been found to be strongly effective against hyperglycemia and hyperlipidemia. METHODS: This study was performed using radioactive D-psicose, which was synthesized enzymatically from radioactive D-allose. Concentrations in whole blood, urine, and organs were measured at different time points until 2 hours after both oral and intravenous administrations and 7 days after a single oral administration (100 mg/kg body weight) to Wistar rats. Autoradiography was also performed by injecting 100 mg/kg body weight of (14)C-labeled D-psicose or glucose intravenously to C3H mice. RESULTS: Following oral administration, D-psicose easily moved to blood. The maximum blood concentration (48.5±15.6 μg/g) was observed at 1 hour. Excretion to urine was 20% within 1 hour and 33% within 2 hours. Accumulation to organs was detected only in the liver. Following intravenous administration, blood concentration was decreased with the half-life=57 minutes, and the excretion to urine was up to almost 50% within 1 hour. Similarly to the results obtained with oral administration, accumulation to organs was detected only in the liver. Seven days after the single-dose oral administration, the remaining amounts in the whole body were less than 1%. Autoradiography of mice showed results similar to those in rats. High signals of (14)C-labeled D-psicose were observed in liver, kidney, and bladder. Interestingly, no accumulation of D-psicose was observed in the brain. CONCLUSION: D-psicose was absorbed well after oral administration and eliminated rapidly after both oral and intravenous administrations, with short duration of action. The study provides valuable pharmacokinetic data for further drug development of D-psicose. Because the findings were mainly based on animal study, it is necessary to implement human trials to study the metabolism pathway, which would give an important guide for human intake and food application of D-psicose.","fulltextAvailable":false,"journal":"Drug design, development and therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eating","uri":{"id":"D004435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Body Weight","uri":{"id":"D001835","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred C3H","uri":{"id":"D008809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Wistar","uri":{"id":"D017208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolic Networks and Pathways","uri":{"id":"D053858","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestinal Absorption","uri":{"id":"D007408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Intravenous","uri":{"id":"D061605","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestines","uri":{"id":"D007422","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney","uri":{"id":"D007668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urination","uri":{"id":"D014554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urine","uri":{"id":"D014556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoradiography","uri":{"id":"D001345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hyperglycemia","uri":{"id":"D006943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hyperlipidemias","uri":{"id":"D006949","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radioactivity","uri":{"id":"D011851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stereoisomerism","uri":{"id":"D013237","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25378908","title":"Intestinal absorption, organ distribution, and urinary excretion of the rare sugar D-psicose.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Organophosphates (OPs) are commonly used insecticides for agriculture and domestic purposes, but may also serve as nerve agents. Exposure to OPs result in overstimulation of the cholinergic system and lead to status epilepticus (SE), a life-threatening condition that is often resistant to treatment. SE is associated with significant neuronal damage, neurocognitive dysfunction, and the development of lifelong epilepsy. Therefore, rapid termination of SE and prevention of brain damage is of high interest. Here we tested the efficacy of sec-butyl-propylacetamide (SPD) and two of its individual stereoisomers, (2S,3S)-SPD and (2R,3R)-SPD, in discontinuing OP-induced seizures. SPD is a one carbon homolog of valnoctamide, a central nervous system (CNS)-active constitutional isomer of valproic acid (VPA) corresponding amide valpromide. METHODS: Rats were implanted with epidural telemetric electrodes to allow electrocorticography (ECoG) recording 24 h prior, during and 24 h after poisoning with the OP paraoxon (at a dose equivalent to 1.4 LD50 Median lethal dose). All rats were provided with antidotal treatment of atropine and toxogonin. Epileptic activity was measured using a novel automated system to evaluate the different effects of midazolam, SPD, and its individual stereoisomers in comparison to nontreated controls. RESULTS: Treatment with SPD or its individual stereoisomer (2S,3S)-SPD significantly shorten paraoxon-induced SE and reduced the duration of recorded pathologic activity after SE was terminated. (2S,3S)-SPD was superior to racemic-SPD in diminishing delayed pathologic epileptiform activity within the first 8 h after SE. SIGNIFICANCE: These results suggest SPD as an efficient drug for the rapid termination of SE and pathological epileptiform activity following OP poisoning, a strategy to reduce neuronal dysfunction and the risk for lifelong epilepsy.","fulltextAvailable":false,"journal":"Epilepsia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Status Epilepticus","uri":{"id":"D013226","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amides","uri":{"id":"D000577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amiloride","uri":{"id":"D000584","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrodes","uri":{"id":"D004566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insecticides","uri":{"id":"D007306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Agriculture","uri":{"id":"D000383","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidotes","uri":{"id":"D000931","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atropine","uri":{"id":"D001285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atropine Derivatives","uri":{"id":"D001286","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lethal Dose 50","uri":{"id":"D007928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Midazolam","uri":{"id":"D008874","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Obidoxime Chloride","uri":{"id":"D009768","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paraoxon","uri":{"id":"D010261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organophosphates","uri":{"id":"D010755","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stereoisomerism","uri":{"id":"D013237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholinergic Agents","uri":{"id":"D018678","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25377630","title":"sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"A few years ago the Food and Drug Administration, based on a meta-analysis, issued a warning stating that antiepileptic drugs (AEDs) are associated with an increased risk of suicidal ideation, suicide attempts, and completed suicide. This warning generated significant concern about the use of AEDs, especially in patients with epilepsy and affective disorders. Following the FDA report, several studies addressed this issue but only served to generate further concern and confusion. There seems to be no convincing data concerning a \"class effect\" of AEDs in inducing any type of suicide-related behaviors. Some data suggest a possible association of lamotrigine, levetiracetam, and topiramate with suicidality, but further research is needed. In any case, clinicians need to carefully assess suicidality in all patients treated with AEDs and inform them and their families on the possible increased risk of suicidality, though preferably in a way that keeps open the continuing use of AEDs.","fulltextAvailable":false,"journal":"Harvard review of psychiatry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mood Disorders","uri":{"id":"D019964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Suicide, Attempted","uri":{"id":"D013406","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Suicidal Ideation","uri":{"id":"D059020","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Suicide","uri":{"id":"D013405","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confusion","uri":{"id":"D003221","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25377614","title":"Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature.","year":"2014 Nov-Dec"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Abstract 1. This study investigated the mechanism underlying Echinacea-mediated induction of CYP1A2, CYP3A4 and MDR1 in terms of human pregnane X receptor (PXR) activation. 2. Crude extracts and fractions of Echinacea purpurea were tested for PXR activation in HepG2 cells by a reporter gene assay. Quantitative real-time PCR was carried out to determine their effects on CYP1A2 and CYP3A4 mRNA expressions. Capsules and fractions were risk ranked as high, intermediate and remote risk of drug-metabolizing enzymes induction based on EC50 values determined for respective CYPs. 3. Fractions F1, F2 and capsule (2660) strongly activated PXR with 5-, 4- and 3.5-fold increase in activity, respectively. Echinacea preparations potentiated up-regulation of CYP1A2, CYP3A4 and MDR1 via PXR activation. 4. Thus E. purpurea preparations cause herb-drug interaction by up-regulating CYP1A2, CYP3A4 and P-gp via PXR activation.","fulltextAvailable":false,"journal":"Xenobiotica; the fate of foreign compounds in biological systems","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Real-Time Polymerase Chain Reaction","uri":{"id":"D060888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Induction","uri":{"id":"D004790","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Reporter","uri":{"id":"D017930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Echinacea","uri":{"id":"D020900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herb-Drug Interactions","uri":{"id":"D041743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complex Mixtures","uri":{"id":"D045424","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hep G2 Cells","uri":{"id":"D056945","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnanes","uri":{"id":"D011278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochrome P-450 CYP1A2","uri":{"id":"D019388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"P-Glycoprotein","uri":{"id":"D020168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Echinacea","uri":{"id":"D020900","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25377539","title":"Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Electroencephalographic (EEG) status epilepticus is described in 10 to 35% of patients with postanoxic encephalopathy after successful cardiopulmonary resuscitation and is associated with case fatality rates of 90 to 100%. It is unclear whether these EEG patterns represent a condition to be treated with anticonvulsants to improve outcome, or an expression of severe ischemic damage, in which treatment is futile. METHODS/DESIGN: TELSTAR is a multicenter clinical trial with two parallel groups, randomized treatment allocation, open label treatment, and blinded endpoint evaluation (PROBE design). We aim to enroll 172 adult patients with postanoxic encephalopathy and electroencephalographic status epilepticus after successful cardiopulmonary resuscitation, admitted to the ICU, in whom continuous EEG monitoring is started within 24 hours after admission. Patients are randomly assigned to either medical treatment to suppress all electrographic seizure activity, or no treatment of electroencephalographic status epilepticus. Antiepileptic treatment is based on guidelines for treatment of overt status epilepticus and is started within 3 hours after the diagnosis. If status epilepticus returns during tapering of sedative medication after suppression of all epileptiform activity for 2 × 24 hours, it will be considered refractory. The primary outcome measure is neurological outcome defined as the Cerebral Performance Category (CPC) score at 3 months, dichotomized into 'good' (CPC 1 to 2 = no or moderate neurological disability) and 'poor' (CPC 3 to 5 = severe disability, coma, or death). Secondary outcome measures include mortality and, for patients surviving up to 12 months, cognitive functioning, health related quality of life, and depression. TRIAL REGISTRATION: Clinicaltrials.gov; NCT02056236. Date of registration: 4 February 2014.","fulltextAvailable":false,"journal":"Trials","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Random Allocation","uri":{"id":"D011897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multicenter Studies as Topic","uri":{"id":"D015337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Futility","uri":{"id":"D018447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Status Epilepticus","uri":{"id":"D013226","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiopulmonary Resuscitation","uri":{"id":"D016887","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electroencephalography","uri":{"id":"D004569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypnotics and Sedatives","uri":{"id":"D006993","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Resuscitation","uri":{"id":"D012151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Futility","uri":{"id":"D018447","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25377067","title":"Treatment of electroencephalographic status epilepticus after cardiopulmonary resuscitation (TELSTAR): study protocol for a randomized controlled trial.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Identifying factors associated with adherence is of great value in clinical practice. The objective of this study was to investigate medication adherence, beliefs about medicines held by people with chronic illness and whether beliefs influence medication adherence. METHODS: The study was carried out at primary health care clinic of the Palestinian Medical Military Services in Nablus, Palestine. The beliefs about medicines questionnaire was used to assess beliefs and Morisky medication adherence scale was used to assess adherence. RESULTS: A total of 187 patients were interviewed. Most participants (79.6%) agreed or strongly agreed that their medications were necessary for their current health. However, 58.2% of the participants were concerned about having to take their medicines on a regular basis and 57.8% were concerned about becoming dependent on their medicines. None of the demographic and clinical variables was significantly associated with medication adherence. However, multivariate analysis showed that patients who had higher beliefs about medication necessity had higher odds (1.107 [1.023-1.197]) of being adherent. On the other hand, patients who had higher concern beliefs had lower odds (0.908 [0.845-0.975]) of being adherent. CONCLUSIONS: Beliefs about medicines are a major contributing factor to medication adherence.","fulltextAvailable":false,"journal":"Journal of family medicine and primary care","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primary Health Care","uri":{"id":"D011320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primary Health Care","uri":{"id":"D011320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arabs","uri":{"id":"D018912","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25374859","title":"Beliefs About Medicines and Self-reported Adherence Among Patients with Chronic Illness: A Study in Palestine.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Synthetic cannabinoids developed by chemical modification are believed to bind to cannabinoid receptors and cause neurological effects similar to cannabis; however, their effects on drug metabolizing enzymes are unknown. This study aimed to elucidate the effect of synthetic cannabinoids on cytochrome P450 1A activity. Naphthoylindole, a basic structure of the major synthetic cannabinoids, strongly inhibited CYP1A activity in a competitive manner; the apparent Ki value was 0.40 μM. The N-Alkylated derivatives of naphthoylindole, MAM-2201 and JWH-019, also inhibited CYP1A activity in a concentration-dependent manner; however, their inhibitory effects were weaker than naphthoylindole. An adamantylamidoindole derivative, STS-135, showed inhibition of CYP1A activity in a concentrationdependent manner, but the adamantoylindole derivatives, AB-001 and AM-1248, did not. A tetramethylcyclopropanoylindole derivative, UR-144, showed a weak inhibition of CYP1A activity at high concentrations. These results suggest that synthetic cannabinoids and their basic molecules are capable of inhibiting CYP1A enzymatic activity.","fulltextAvailable":false,"journal":"The Journal of toxicological sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochrome P-450 Enzyme System","uri":{"id":"D003577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microsomes, Liver","uri":{"id":"D008862","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Cannabinoid","uri":{"id":"D043882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabinoids","uri":{"id":"D002186","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochromes","uri":{"id":"D003580","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cannabis","uri":{"id":"D002188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microsomes","uri":{"id":"D008861","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25374372","title":"Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Abstract This was a systematic review of randomized controlled trials comparing anticonvulsants with placebo or no anticonvulsant for prevention: a) of eclampsia in women with severe preeclampsia diagnosed during the postpartum period or diagnosed before delivery but without previous treatment and, b) prevention of seizures recurrence in women with eclampsia postpartum. We do not found study with full inclusion criteria. However, a total of two RCTs meet inclusion criteria as subgroup analysis; one for severe preeclampsia diagnosed during the postpartum period and one for eclampsia postpartum. For severe preeclampsia diagnosed during postpartum there was no clear difference between the groups reporting eclampsia (RR 0.54, 95% CI 0.16 to 1.80). For seizure recurrence magnesium sulfate was superior to diazepam, but there was no significant difference compared with phenytoin. This review did not support a beneficial effect of magnesium sulfate in women with diagnosis of severe preeclampsia during the postpartum.","fulltextAvailable":false,"journal":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postpartum Period","uri":{"id":"D049590","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnesium Sulfate","uri":{"id":"D008278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eclampsia","uri":{"id":"D004461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnesium","uri":{"id":"D008274","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pre-Eclampsia","uri":{"id":"D011225","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postpartum Period","uri":{"id":"D049590","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diazepam","uri":{"id":"D003975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenytoin","uri":{"id":"D010672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfates","uri":{"id":"D013431","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25373431","title":"The Use Of Magnesium Sulphate For Women With Severe Preeclampsia Or Eclampsia Diagnosed During The Postpartum Period.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To evaluate the impact of long-term zolpidem use on the subsequent risk of epilepsy. METHOD: We used data from the National Health Insurance system of Taiwan to conduct a population-based case-control study. We identified 4,972 newly diagnosed epilepsy patients (ICD-9-CM code 345) for the period of 2005-2010 as cases. For each epilepsy case, 4 controls without a history of epilepsy were randomly selected from the rest of the population. Zolpidem was used as a predictor of epilepsy. RESULTS: Patients with epilepsy exhibited an adjusted odds ratio (OR) of 1.86 (95% CI, 1.70-2.03) and were, therefore, more strongly associated with zolpidem exposure than control patients were. The adjusted OR of epilepsy increased with the increase of mean zolpidem exposure (g/y). Compared with the OR of nonusers, the adjusted OR was 1.64 (95% CI, 1.44-1.86) for those who had taken < 1.0 g/y of zolpidem and 2.38 (95% CI, 2.06-2.74) for those who had taken ≥ 20.0 g/y of zolpidem. An adjusted OR of 3.55 (95% CI, 2.94-4.28) was noted to be associated with epilepsy when users had stopped taking the drug less than 7 days earlier. The estimated risk declined to an OR of 1.62 (95% CI, 1.47-1.78) when users had stopped taking the drug more than 90 days earlier. CONCLUSIONS: This population-based, retrospective case-control study revealed a possible increase in epilepsy risk with zolpidem use, at either typical or supratherapeutic doses. These findings might stimulate public interest in safety issues regarding zolpidem use.","fulltextAvailable":false,"journal":"The Journal of clinical psychiatry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Health Programs","uri":{"id":"D009313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance, Health","uri":{"id":"D007348","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rest","uri":{"id":"D012146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Taiwan","uri":{"id":"D013624","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance","uri":{"id":"D007341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance Carriers","uri":{"id":"D007343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Diseases","uri":{"id":"D038801","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25373122","title":"Association of zolpidem use and subsequent increased risk of epilepsy: a population-based, case-control study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To apply discovery-based computational methods to nationally representative data from the Centers for Disease Control and Preventions' Youth Risk Behavior Surveillance System to better understand and visualize the behavioral factors associated with gun possession among adolescent youth. RESULTS: Our study uncovered the multidimensional nature of gun possession across nearly five million unique data points over a ten year period (2001-2011). Specifically, we automated odds ratio calculations for 55 risk behaviors to assemble a comprehensive table of associations for every behavior combination. Downstream analyses included the hierarchical clustering of risk behaviors based on their association \"fingerprint\" to 1) visualize and assess which behaviors frequently co-occur and 2) evaluate which risk behaviors are consistently found to be associated with gun possession. From these analyses, we identified more than 40 behavioral factors, including heroin use, using snuff on school property, having been injured in a fight, and having been a victim of sexual violence, that have and continue to be strongly associated with gun possession. Additionally, we identified six behavioral clusters based on association similarities: 1) physical activity and nutrition; 2) disordered eating, suicide and sexual violence; 3) weapon carrying and physical safety; 4) alcohol, marijuana and cigarette use; 5) drug use on school property and 6) overall drug use. CONCLUSIONS: Use of computational methodologies identified multiple risk behaviors, beyond more commonly discussed indicators of poor mental health, that are associated with gun possession among youth. Implications for prevention efforts and future interdisciplinary work applying computational methods to behavioral science data are described.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nutrition Disorders","uri":{"id":"D009748","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mental Health","uri":{"id":"D008603","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Motor Activity","uri":{"id":"D009043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sex Offenses","uri":{"id":"D012742","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Behavioral Sciences","uri":{"id":"D001525","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Centers for Disease Control and Prevention (U.S.)","uri":{"id":"D002487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computing Methodologies","uri":{"id":"D003205","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk-Taking","uri":{"id":"D012309","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eating","uri":{"id":"D004435","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indicators and Reagents","uri":{"id":"D007202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schools","uri":{"id":"D012574","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Science","uri":{"id":"D012586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Suicide","uri":{"id":"D013405","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Violence","uri":{"id":"D014754","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cluster Analysis","uri":{"id":"D016000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lifting","uri":{"id":"D017770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sexuality","uri":{"id":"D019529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Theory of Mind","uri":{"id":"D056345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heroin","uri":{"id":"D003932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tobacco, Smokeless","uri":{"id":"D014030","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Weapons","uri":{"id":"D054041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tobacco Products","uri":{"id":"D062789","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25372864","title":"Gun Possession among American Youth: A Discovery-Based Approach to Understand Gun Violence.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Therapeutic drugs for cognitive and psychiatric disorders are often characterized by their molecular mechanism of action. Here we demonstrate a new approach to elucidate drug action on large-scale neuronal activity by tracking somatic calcium dynamics in hundreds of CA1 hippocampal neurons of pharmacologically manipulated behaving mice. We used an adeno-associated viral vector to express the calcium sensor GCaMP3 in CA1 pyramidal cells under control of the CaMKII promoter and a miniaturized microscope to observe cellular dynamics. We visualized these dynamics with and without a systemic administration of Zolpidem, a GABAA agonist that is the most commonly prescribed drug for the treatment of insomnia in the United States. Despite growing concerns about the potential adverse effects of Zolpidem on memory and cognition, it remained unclear whether Zolpidem alters neuronal activity in the hippocampus, a brain area critical for cognition and memory. Zolpidem, when delivered at a dose known to induce and prolong sleep, strongly suppressed CA1 calcium signaling. The rate of calcium transients after Zolpidem administration was significantly lower compared to vehicle treatment. To factor out the contribution of changes in locomotor or physiological conditions following Zolpidem treatment, we compared the cellular activity across comparable epochs matched by locomotor and physiological assessments. This analysis revealed significantly depressive effects of Zolpidem regardless of the animal's state. Individual hippocampal CA1 pyramidal cells differed in their responses to Zolpidem with the majority (∼65%) significantly decreasing the rate of calcium transients, and a small subset (3%) showing an unexpected and significant increase. By linking molecular mechanisms with the dynamics of neural circuitry and behavioral states, this approach has the potential to contribute substantially to the development of new therapeutics for the treatment of CNS disorders.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dependovirus","uri":{"id":"D000229","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyramidal Cells","uri":{"id":"D017966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium Signaling","uri":{"id":"D020013","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium","uri":{"id":"D002118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cognition","uri":{"id":"D003071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sleep Initiation and Maintenance Disorders","uri":{"id":"D007319","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Track and Field","uri":{"id":"D014142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Advance Directives","uri":{"id":"D016223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hippocampus","uri":{"id":"D006624","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Miniaturization","uri":{"id":"D008904","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium-Calmodulin-Dependent Protein Kinase Type 2","uri":{"id":"D054732","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25372144","title":"Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies. This multicenter, randomized, open-label, crossover study evaluated whether Chinese men with ED preferred 20-mg tadalafil or 100-mg sildenafil. After a 4 weeks baseline assessment, 383 eligible patients were randomized to sequential 20-mg tadalafil per 100-mg sildenafil or vice versa for 8 weeks respectively and then chose which treatment they preferred to take during the 8 weeks extension. Primary efficacy was measured by Question 1 of the PDE5 Inhibitor Treatment Preference Questionnaire (PITPQ). Secondary efficacy was analyzed by PITPQ Question 2, the International Index of Erectile Function (IIEF) erectile function (EF) domain, sexual encounter profile (SEP) Questions 2 and 3, and the Drug Attributes Questionnaire. Three hundred and fifty men (91%) completed the randomized treatment phase. Two hundred and forty-two per 350 (69.1%) patients preferred 20-mg tadalafil, and 108/350 (30.9%) preferred 100-mg sildenafil (P < 0.001) as their treatment in the 8 weeks extension. Ninety-two per 242 (38%) patients strongly preferred tadalafil and 37/108 (34.3%) strongly the preferred sildenafil. The SEP2 (penetration), SEP3 (successful intercourse), and IIEF-EF domain scores were improved in both tadalafil and sildenafil treatment groups. For patients who preferred tadalafil, getting an erection long after taking the medication was the most reported reason for tadalafil preference. The only treatment-emergent adverse event reported by > 2% of men was headache. After tadalafil and sildenafil treatments, more Chinese men with ED naοve to PDE5 inhibitor preferred tadalafil. Both sildenafil and tadalafil treatments were effective and safe.","fulltextAvailable":false,"journal":"Asian journal of andrology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphodiesterase Inhibitors","uri":{"id":"D010726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclic Nucleotide Phosphodiesterases, Type 5","uri":{"id":"D054706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphodiesterase 5 Inhibitors","uri":{"id":"D058986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Preference","uri":{"id":"D057240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erectile Dysfunction","uri":{"id":"D007172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Over Studies","uri":{"id":"D018592","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclic Nucleotide Phosphodiesterases, Type 5","uri":{"id":"D054706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphodiesterase 5 Inhibitors","uri":{"id":"D058986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Men","uri":{"id":"D008571","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sexuality","uri":{"id":"D019529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrates","uri":{"id":"D002951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Headache","uri":{"id":"D006261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphoric Diester Hydrolases","uri":{"id":"D010727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citric Acid","uri":{"id":"D019343","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25370206","title":"An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.","year":"2014"}